Compounds and methods for the treatment of cancer

ABSTRACT

Compositions and methods relating to induction of cell death such as in cancer cells are disclosed. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds in connection with modification of procaspases such as procaspase-3 are disclosed. In various embodiments, the compounds and compositions are capable of activation of procaspase-3.

RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.15/385,040, filed Dec. 20, 2016, issued as U.S. Pat. No. 10,166,229,which is a continuation of U.S. patent application Ser. No. 13/893,936,filed May 14, 2013, issued as U.S. Pat. No. 9,552,901, which is acontinuation of U.S. patent application Ser. No. 13/087,595, filed Apr.15, 2011, issued as U.S. Pat. No. 8,592,584, which is a continuation ofU.S. patent application Ser. No. 12/597,287, filed Oct. 23, 2009, whichis a National Stage filing under 35 U.S.C. § 371 of InternationalApplication No. PCT/US2008/061510, filed Apr. 25, 2008, which claims thebenefit of U.S. provisional application 60/914,592, filed Apr. 27, 2007,and U.S. patent application Ser. No. 13/087,595, filed Apr. 15, 2011,issued as U.S. Pat. No. 8,592,584 which is a continuation-in-part ofU.S. patent application Ser. No. 11/420,425, filed May 25, 2006, whichclaims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional PatentApplication No. 60/743,878, filed Mar. 28, 2006 and U.S. ProvisionalPatent Application No. 60/684,807, filed May 26, 2005, each of which isincorporated herein by reference.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Nov. 4, 2013, isnamed 500-030us2_SL.txt and is 94,980 bytes in size.

BACKGROUND OF THE INVENTION

Apoptosis, or programmed cell death, plays a central role in thedevelopment and homeostasis of all multicellular organisms (Shi Y, 2002,Molecular Cell 9:459-470). A frequent hallmark of cancer is resistanceto natural apoptotic signals. Depending on the cancer type, thisresistance is typically due to up- or down-regulation of key proteins inthe apoptotic cascade or to mutations in genes encoding these proteins.Such changes occur in both the intrinsic apoptotic pathway, whichfunnels through the mitochondria and caspase-9, and the extrinsicapoptotic pathway, which involves the action of death receptors andcaspase-8. For example, alterations in proper levels of proteins such asp53, Bim, Bax, Apaf-1, FLIP and many others have been observed incancers. The alterations can lead to a defective apoptotic cascade, onein which the upstream pro-apoptotic signal is not adequately transmittedto activate the executioner caspases, caspase-3 and caspase-7.

As most apoptotic pathways ultimately involve the activation ofprocaspase-3, upstream genetic abnormalities are effectively “breaks” inthe apoptotic circuitry, and as a result such cells proliferateatypically. Given the central role of apoptosis in cancer, efforts havebeen made to develop therapeutics that target specific proteins in theapoptotic cascade. For instance, peptidic or small molecule binders tocascade members such as p53 and proteins in the Bcl family or to theinhibitor of apoptosis (IAP) family of proteins have pro-apoptoticactivity, as do compounds that promote the oligomerization of Apaf-1.However, because such compounds target early (or intermediate to high)positions on the apoptotic cascade, cancers with mutations in proteinsdownstream of those members can still be resistant to the possiblebeneficial effects of those compounds.

For therapeutic purposes it would be advantageous to identify a smallmolecule that directly activates a proapoptotic protein far downstreamin the apoptotic cascade. The approach to our invention involves such arelatively low position in the cascade, thus enabling the killing ofeven those cells that have mutations in their upstream apoptoticmachinery. Moreover, the therapeutic strategies disclosed herein canhave a higher likelihood of success if that proapoptotic protein wereupregulated in cancer cells. In the present invention, our efforts toidentify small molecules began with targeting the significant downstreameffector protein of apoptosis, procaspase-3.

The conversion or activation of procaspase-3 to caspase-3 results in thegeneration of the active “executioner” caspase form that subsequentlycatalyzes the hydrolysis of a multitude of protein substrates. Activecaspase-3 is a homodimer of heterodimers and is produced by proteolysisof procaspase-3. In vivo, this proteolytic activation typically occursthrough the action of caspase-8 or caspase-9. To ensure that theproenzyme or zymogen is not prematurely activated, procaspase-3 has a12-amino acid “safety catch” that blocks access to the IETD site (aminoacid sequence, ile-glu-thr-asp) of proteolysis. See Roy, S. et al.;Maintenance of caspase-3 proenzyme dormancy by an intrinsic “safetycatch” regulatory tripeptide, Proc. Natl. Acad. Sci. 98, 6132-6137(2001).

This safety catch enables procaspase-3 to resist autocatalyticactivation and proteolysis by caspase-9. Mutagenic studies indicate thatthree consecutive aspartic acid residues appear to be the criticalcomponents of the safety catch. The position of the safety catch issensitive to pH; thus, upon cellular acidification (as occurs duringapoptosis) the safety catch is thought to allow access to the site ofproteolysis, and active caspase-3 can be produced either by the actionof caspase-9 or through an autoactivation mechanism.

In particular cancers, the expression of procaspase-3 is upregulated. Astudy of primary isolates from 20 colon cancer patients revealed that onaverage, procaspase-3 was upregulated six-fold in such isolates relativeto adjacent non-cancerous tissue (Roy et al., 2001). In addition,procaspase-3 is upregulated in certain neuroblastomas, lymphomas, andliver cancers (Nakagawara, A. et al., 1997, Cancer Res. 57:4578-4584;Izban, K. F. et al., Am. J. Pathol. 154:1439-1447; Persad, R. et al.,Modern Patholo. 17:861-867). Furthermore, a systematic evaluation wasperformed of procaspase-3 levels in the 60 cell-line panel used forcancer screening by the National Cancer Institute (NCI) DevelopmentalTherapeutics Program. The evaluation revealed that certain lung,melanoma, renal, and breast cancers show greatly enhanced levels ofprocaspase-3 expression (Svingen, P. A. et al., Clin. Cancer Res.10:6807-6820).

Due to the role of active caspase-3 in achieving apoptosis, therelatively high expression levels of procaspase-3 in certain cancerouscell types, and the intriguing safety catch-mediated suppression of itsautoactivation, we reasoned that small molecules that directly modifyprocaspase-3 could be identified and that such molecules could havegreat applicability in targeted cancer therapy.

Herein we disclose, inter alia, compositions and methods including smallmolecules capable of inducing cell death. In embodiments, compositionsand methods involve compounds which can interact directly or indirectlywith programmed cell death pathway members such as procaspase-3.

U.S. Provisional Application No. 60/684,807 filed May 26, 2005; U.S.Provisional Application No. 60/743,878 filed Mar. 28, 2006; U.S. patentapplication Ser. No. 11/420,425 filed May 25, 2006 (published as US2007/0049602, Mar. 1, 2007); PCT International Application No.PCT/US2006/020910 filed May 26, 2006 (published as WO 2006/128173, Nov.30, 2006), which are incorporated by reference herein, relate to thesubject matter of the present application.

SUMMARY

The invention broadly provides compounds, methods of therapeutictreatment, methods of screening for compounds, and methods of screeningfor cell and patient suitability for treatment in connection withmodifiers of procaspases. In an embodiment, the modifiers areinhibitors. In an embodiment, the modifiers are activators. In anembodiment, the invention provides such compounds and methods inconnection with activators of procaspase-3 and procaspase-7. Inembodiments, the inventions are applicable in the context of a varietyof cancer diseases and cancer cell types such as breast, lymphoma,adrenal, renal, melanoma, leukemia, neuroblastoma, lung, brain, andothers known in the art.

As a further introduction, compounds capable of activating an enzymethat is often overexpressed in its inactive form in cancer cells havebeen discovered. The compound induces programmed cell death (apoptosis)in cancer cells, including those that have upregulated procaspase-3.Many cancers resist standard chemotherapy. Compounds of the inventioncan take advantage of a biological target that may be upregulated incancer cells and thus can prove effective even in cells with defects intheir apoptotic machinery. These compounds can also be successful intargeted cancer therapy, where there can be advantages of selectivity inthe killing of cancer cells with comparably reduced toxicity tonon-cancerous cells having lower levels of procaspase-3.

Without wishing to be bound by a particular theory, it is believed thatembodiments of compounds and methods of the invention may act via themechanism of modulation of apoptosis or programmed cell death to beeffective in the treatment of cancer cells. In a preferred embodiment,the modulation of apoptosis is by induction of apoptosis. In anotherembodiment, the modulation of apoptosis is by inhibition of apoptosis.

In an embodiment, the invention provides a method of selectivelyinducing apoptosis in a cancer cell, comprising: (a) administering tosaid cancer cell an effective amount of a compound capable of modifyinga procaspase-3 molecule of said cancer cell; and (b) modifying saidprocaspase-3 molecule so as to induce apoptosis. In an embodiment, saidcancer cell is in a patient in need of treatment.

In an embodiment, compounds and methods may act indirectly in connectionwith a programmed cell death pathway member, e.g., procaspase-3, such asby chelating or otherwise interacting directly or indirectly with amolecule which is necessary for the pathway member. In an embodiment,the molecule is a metal such as zinc.

In an embodiment, said compound is of formula Z:

and salts thereof,

wherein n=0, 1 or 2;

each R, independently of other R, is selected from hydrogen, halogen,alkyl, alkoxy or alkenyl;

R₂X is a halogen or X is O, S, NR₇, CO, OCO, or OCS, when X is O or S,R₂=hydrogen, alkyl, aryl, R₈CO—, R₈OCO—, R₈SCO, R₈OCS— or a moiety thatis removable under physiological conditions, where R₈ is alkyl or aryl,when X is NR₇, R₂ and R₇, independently, are selected from hydrogen,alkyl, aryl, R₈CO—, R₈OCO—, or a moiety that is removable underphysiological conditions; when X is CO, OCO or OCS, R₂ is hydrogen,alkyl, aryl, or a moiety that is removable under physiologicalconditions;

R₃ is selected from hydrogen, halogen, alkyl, haloalkyl, alkenyl,alkenol, alkanol, or haloalkenyl;

R₄ and R₅ are both N; R₄ is N and R₅ is CH; R₄ is CH and R₅ is N or R₄and R₅ are both CH;

R₆ is hydrogen or alkyl;

A=oxygen or sulfur; and

B is aryl, heteroaryl or R₉—O—CO—, where R₉ is alkyl or aryl.

In a more specific embodiment of formula Z, R₃ is allyl. In anotherembodiment of formula Z, R₂X is OH. In another embodiment of formula Z,R₂X is NH₂. In specific embodiments, aryl groups are phenyl groupssubstituted with one or more R groups as defined above. In specificembodiments, alkyl groups are C1-C6 alkyl groups or C1-C3 alkyl groups.In specific embodiments, alkenyl groups are C2-C6 alkenyl groups orC2-C4 alkenyl groups. In specific embodiments, alkenyl groups are allylgroups. In specific embodiments of formula Z, B is a R₉—O—CO—. Inspecific embodiments of formula Z, B is a phenyl substituted with one ormore R substituents. In specific embodiments of formula Z, R₉ is at-butyl group. In specific embodiments, R₆ is hydrogen or methyl. Inspecific embodiments, n is 0 and B is R₉—O—CO—. In specific embodiments,n is 1 or 2 and B is aryl. In a specific embodiment, A is O. In aspecific embodiment, R is hydrogen. In a specific embodiment of formulaZ, at least one R or R₃ is a substituent other than hydrogen. In aspecific embodiment of formula Z, at least one R is a substituent otherthan hydrogen. In a specific embodiment of formula Z, R₂X is OH and R₃is allyl. In a specific embodiment of formula Z, n is 1 and B ispyridinyl. In a specific embodiment of formula Z, n is 1 and B is2-pyridinyl. In a specific embodiment of formula Z, n is 1 and B is3-pyridinyl. In a specific embodiment of formula Z, n is 1 and B is4-pyridinyl. In specific embodiments of formula Z, n is 0 and B isR₉—OCO— and R₉ is alkyl. In specific embodiments of formula Z, n is 0and B is R₉—OCO— and R₉ is t-butyl.

In an embodiment, said compound is of formula ZA:

and salts thereof;

wherein each R, independently of other R, is selected from hydrogen,halogen, alkyl, or alkenyl;

R₂X is a halogen or X is O, S, NR₇, CO, OCO, or OCS, when X is O or S,R₂=hydrogen, alkyl, aryl, R₈CO—, R₈OCO—, R₈SCO, R₈OCS— or a moiety thatis removable under physiological conditions, where R₈ is alkyl or aryl,when X is NR₇, R₂ and R₇, independently, are selected from hydrogen,alkyl, aryl, R₈CO—, R₈OCO—, or a moiety that is removable underphysiological conditions; when X is CO, OCO or OCS, R₂ is hydrogen,alkyl, aryl, or a moiety that is removable under physiologicalconditions;

R₃ is selected from hydrogen, halogen, alkyl, haloalkyl, alkenyl,alkenol, alkanol, or haloalkenyl;

R₄ and R₅ are both N; R₄ is N and R₅ is CH; R₄ is CH and R₅ is N or R₄and R₅ are both CH;

R₆ is hydrogen or alkyl;

A=oxygen or sulfur; and

R₉ is alkyl or aryl.

In a more specific embodiment of formula ZA, R₃ is allyl. In specificembodiments of formula ZA, R₉ is an alkyl group. In specific embodimentsof formula ZA, R₉ is an C1-C6 alkyl group. In specific embodiments, R₉is a t-butyl group. In another embodiment of formula ZA, R₂X is OH. Inanother embodiment of formula ZA, R₂X is NH₂. In specific embodiments offormula ZA, aryl groups are phenyl groups substituted with one or more Rgroups as defined above. In specific embodiments of formula ZA, alkylgroups are C1-C6 alkyl groups or C1-C3 alkyl groups. In specificembodiments of formula ZA, alkenyl groups are C2-C6 alkenyl groups orC2-C4 alkenyl groups. In specific embodiments of formula ZA, alkenylgroups are allyl groups. In specific embodiments of formula ZA, R₆ ishydrogen or methyl. In a specific embodiment of formula ZA, A is O. In aspecific embodiment of formula ZA, R is hydrogen. In a specificembodiment of formula ZA, at least one R or R₃ is a substituent otherthan hydrogen. In a specific embodiment of formula ZA, at least one R isa substituent other than hydrogen. In a specific embodiment of formulaZA, R₂X is OH and R₃ is allyl.

In an embodiment, said compound is of formula ZZ:

and salts thereof,

wherein n=1 or 2; Ra, Rb, Rc, Rd, and Re are independently selected fromhydrogen, halogen, alkyl, alkenyl, alkoxy, and aryl and other variablesare as defined in formula Z.

In a specific embodiment of formula ZZ, n is 1. In a specific embodimentof formula ZZ, R₂X is OH. In a specific embodiment of formula ZZ, R₂X isNH₂. In a specific embodiment of formula ZZ, A is O. In a specificembodiment of formula ZZ, R₃ is allyl. In a specific embodiment offormula ZZ, R₆ is hydrogen. In a specific embodiment of formula ZZ, R ishydrogen. In a specific embodiment of formula ZZ, one or two of Ra, Rb,Rc, Rd and Re are C1-C3 alkyl, C1-C3 alkoxy or halogens and theremaining groups are hydrogens. In a specific embodiment, Rc is a C1-C3alkyl or a C1-C3 alkoxy and Ra, Rb, Rd, and Re are all hydrogens. In aspecific embodiment, all of Ra, Rb, Rc, Rd and Re are hydrogens. In aspecific embodiment, Rc is fluorine and Ra, Rb, Rc, Rd and Re are allhydrogens. In a specific embodiment, R₂X is chlorine. In a specificembodiment, R₂X is OH. In a specific embodiment, R₂X is SH. In aspecific embodiment, R₂X is CH₃S. In a specific embodiment, R₂X isHO—CO—. In a specific embodiment, R₂X is CH₃O—CO—.

In additional embodiments of formula ZZ, R₄ and R₅ are both N, A isoxygen, and other variable groups are as defined above. In an embodimentof formula ZZ, R₄ and R₅ are both N, A is oxygen, R₂ is hydrogen, andother variable groups are as defined above. In an embodiment of formulaZZ, R₄ and R₅ and both N, A is oxygen, R₂ is hydrogen, R₃ is allyl, andother variable groups are as defined above. In an embodiment of ZZ, oneof R is a fluorine. In a specific embodiment of formula ZZ, at least oneR or R₃ is a substituent other than hydrogen. In a specific embodimentof formula ZZ, at least one R is a substituent other than hydrogen. In aspecific embodiment of formula ZZ, R₂X is OH and R₃ is allyl. In aspecific embodiment of formula ZZ, at least one of Ra-Re is asubstituent other than hydrogen. In a specific embodiment of formula ZZ,at least one R or R₃ is a substituent other than hydrogen, and at leastone of Ra-Re is a substituent other than hydrogen.

In an embodiment, the invention provides compounds of formula ZB:

or salts thereof,

where m is 1-4 and other variables are as defined for formula Z. Inspecific embodiments of formula ZB, m is 2. In additional embodiments offormula ZB, R₄ and R₅ are both N. In an embodiment of formula ZB, R₃ isallyl. In specific embodiments of formula ZB, B is aryl. In specificembodiments of formula ZB, B is R₉—O—CO—. In another embodiment offormula ZB, R₂X is OH. In another embodiment of formula ZB, R₂X is NH₂.In specific embodiments of formula ZB, aryl groups are phenyl groupssubstituted with one or more R groups as defined above. In specificembodiments of formula ZB, alkyl groups are C1-C6 alkyl groups or C1-C3alkyl groups. In specific embodiments of formula ZB, alkenyl groups areC2-C6 alkenyl groups or C2-C4 alkenyl groups. In specific embodiments offormula ZB, alkenyl groups are allyl groups. In specific embodiments offormula ZB, R₉ is a t-butyl group. In specific embodiments of formulaZB, R₆ is hydrogen or methyl. In specific embodiments of formula ZB, nis 0 and B is R₉—O—CO—. In specific embodiments, n is 1 or 2 and B isaryl. In a specific embodiment of formula ZB, R is hydrogen. In aspecific embodiment of formula ZB, at least one R or R₃ is a substituentother than hydrogen. In a specific embodiment of formula ZB, at leastone R is a substituent other than hydrogen. In a specific embodiment offormula ZB, R₂X is OH and R₃ is allyl.

In an embodiment, the invention provides compounds of formula ZC:

and salts thereof,

where q is 1 or 2 and other variables are as defined for formula Z.

In a specific embodiment of formula ZC, q is 2. In a specific embodimentof formula ZC, R₃ is allyl. In another embodiment of formula ZC, R₂X isOH. In another embodiment of formula ZC, R₂X is NH₂. In specificembodiments of formula ZC, aryl groups are phenyl groups substitutedwith one or more R groups as defined above. In specific embodiments offormula ZC, alkyl groups are C1-C6 alkyl groups or C1-C3 alkyl groups.In specific embodiments of formula ZC, alkenyl groups are C2-C6 alkenylgroups or C2-C4 alkenyl groups. In specific embodiments of formula ZC,alkenyl groups are allyl groups. In specific embodiments of formula ZC,B is a R₉—O—CO—. In specific embodiments of formula ZC, B is a phenylsubstituted with one or more R substituents. In specific embodiments offormula ZC, R₉ is a t-butyl group. In specific embodiments, R₆ ishydrogen or methyl. In specific embodiments of formula ZC, n is 0 and Bis R₉—O—CO—. In specific embodiments of formula ZC, n is 1 or 2 and B isaryl. In a specific embodiment of formula ZC, A is O. In a specificembodiment of formula ZC, R is hydrogen. In a specific embodiment offormula ZC, at least one R or R₃ is a substituent other than hydrogen.In a specific embodiment of formula ZC, at least one R is a substituentother than hydrogen. In a specific embodiment of formula ZC, R₂X is OHand R₃ is allyl.

In an embodiment, the invention provides compounds of formula ZD:

and salts thereof, where each of R₆ and R′₆ is independently selectedfrom hydrogen or alkyl and other variables are as defined in formula Z.

In specific embodiments of formula ZD, R₆ is hydrogen or methyl and R′₆is hydrogen. In specific embodiments of formula ZD, R′₆ is hydrogen. Inspecific embodiments of formula ZD, n is 1 and B is aryl. In specificembodiments of formula ZD, n is 1 and B is phenyl substituted with oneor more R groups as defined above. In specific embodiments of formulaZD, A is O.

In an embodiment, the invention provides compounds of formula ZY:

and salts thereof,where Y is selected from any one of:

Y1=—CH₂—CO—NR₆—N═CH—,

Y2=—CH₂—CO—NR₆—NR′₆—CH₂—,

Y3=—CH₂—CH₂—NR₆—N═CH—,

Y4=—CH₂—CH₂—NR₆—NR′₆—CH₂—,

Y5=—CH₂—CO—NH—CH₂—CH₂—, or

Y6=—CH₂—CO—NH—CH₂—;

R₅ is CH or N, and other variables are as defined in the formulas above.

In specific embodiments of formula ZX, n is 1 and B is aryl orheteroaryl. In specific embodiments of formula ZX, n is 1 and B isphenyl, R-substituted phenyl or pyridinyl. In specific embodiments offormula ZX, Y is Y2, Y3, or Y4. In specific embodiments of formula ZX, Yis Y5 or Y6. in specific embodiments, R₅ is CH or N. In specificembodiments, R₅ is N. In specific embodiments, Y is Y1, n is 0 and B isR₉—O—CO—. In specific embodiments, n is 0 and B is B is R₉—O—CO—. Inspecific embodiments R² X is OH. In specific embodiments, R₂ X is —NH₂.In specific embodiments R² X is OH and R₃ is allyl. In specificembodiments, R₂ X is —NH₂ and R₃ is allyl. In specific embodiments, atleast one of R is a non-hydrogen substituent. In specific embodiments,R₆ is hydrogen or methyl. In specific embodiments, R′₆ is hydrogen.

In an embodiment, the invention provides compounds of formula GX:

and salts thereof, where variables are as defined above.

In specific embodiments Y is Y1. In other specific embodiments, Y is Y1and B is aryl. In other specific embodiments R₅ is N. In other specificembodiments, R and R₃ are all hydrogens. In other specific embodiments,B is aryl. In other specific embodiments, n is 1 or 2. In other specificembodiments, B is phenyl and RA represents substitution with hydrogenson the phenyl ring. IN other embodiments, Y is Y1, A is O and R₆ ishydrogen. In other specific embodiments, Y is Y1, n is 1, B isoptionally substituted phenyl. In other embodiments, B is R₉—COO—. Inother embodiments R₉ is C1-C6 alkyl and more specifically is t-butyl. Inother specific embodiments, Y is Y1, R₅ is N, n is 0 and B is optionallysubstituted phenyl. In other specific embodiments, Y is Y1, R₅ is N, nis 0 and B is R₉—COO—. In specific embodiments Y is Y2 or Y4. In otherspecific embodiments, Y is Y1 or Y3. In other specific embodiments, Y isY5 or Y6.

In an embodiment, a compound is provided wherein B is a phenyl with atleast one substituent other than hydrogen. In an embodiment, a compoundis provided wherein the aromatic ring shown on the right side ofcompound ZY (or its analogous equivalent in other compounds describedherein) has at least one substituent other than hydrogen. In anembodiment, a compound is provided wherein both rings have at least onesubstituent other than hydrogen.

In an embodiment, the method further comprises the step of assessing aprocaspase-3 or caspase-3 parameter in a cancer cell; wherein saidparameter is one or more of a semi-quantitative or quantitative amount,a functional amount, and an activity level of said procaspase-3 orcaspase-3.

In an embodiment, the invention provides a method of direct in vitroscreening for a compound capable of modifying a procaspase-3 molecule,comprising: (a) providing a test compound; (b) providing a purifiedprocaspase-3; (c) exposing the test compound to the purifiedprocaspase-3; (d) measuring a procaspase-3 activity following exposureto the test compound; (e) identifying a modifying compound by comparinga test activity upon the exposure to the test compound with anunmodified activity in the absence of exposure to the test compound;thereby screening for a compound capable of modifying a procaspase-3molecule. In an embodiment, the method further comprises comparing saidmodified activity or said unmodified activity with a reference activity;wherein said reference activity is due to exposure of procaspase-3 to acompound selected from the group consisting of structural formula Z, ZA,ZB, ZC, ZD, ZZ, PAC-1 or Compound 5.

In an embodiment, the invention provides a method of screening for acompound capable of activating procaspase-3 comprising: a) providingprocaspase-3; providing a test compound, preferably a small molecule; b)reacting the procaspase-3 with the test compound, thereby putativelygenerating caspase-3; and c) measuring caspase-3 activity. In aparticular embodiment, the measuring caspase-3 activity employs asubstrate, Ac-DEVD-pNA (SEQ ID NO: 28). In a particular embodiment, themeasuring uses a wavelength readout parameter of about 410 nm. In aparticular embodiment, the screening is carried out in parallel usingmultiple test compounds.

In an embodiment, the invention provides a method of screening whichuses the detection of a subunit of procaspase-3 as an indicator that thefull length (inactive) procaspase-3 is processed to caspase-3. In aparticular embodiment, the subunit has a molecular weight of about 19 kDas measured by a protein gel migration technique, for example in aWestern blot.

In an embodiment, the invention provides a method of in cellularscreening for a compound capable of modifying a procaspase-3 molecule,comprising: (a) providing a test compound; (b) providing a cell, whereinthe cell putatively expresses procaspase-3; (c) exposing the cell to thetest compound; (d) measuring a cell parameter following exposure to thetest compound; wherein said parameter comprises one or more of cellviability, apoptotic indicator, and other parameters; (e) identifying amodifying compound by comparing a tested cell parameter upon theexposure to the test compound with an unmodified cell parameter in theabsence of exposure to the test compound; thereby screening for acompound capable of modifying a procaspase-3 molecule. In an embodiment,the method further comprises comparing said modified activity or saidunmodified activity with a reference activity; wherein said referenceactivity is due to exposure to a compound selected from the groupconsisting of formula Z, ZA, ZB, ZC, ZD, or ZZ or subsets of compoundsof such formula, PAC-1, and Compound 5.

In an embodiment, the invention provides a method of identifying ordiagnosing a potential susceptibility to treatment for a cancer cellwith a procaspase activator compound, comprising (a) assessing aprocaspase parameter in said cancer cell; and (b) determining if saidparameter allows an increased susceptibility to activation of aprocaspase. In an embodiment, said procaspase parameter is aprocaspase-3 level and said procaspase is procaspase-3. In anembodiment, said procaspase parameter is a procaspase-7 level and saidprocaspase is procaspase-7. A level can be a semi-quantitative orquantitative amount, or functional amount (e.g. an activity-basedamount, e.g. a standardized unit or international unit).

In an embodiment, the invention provides a method of treating a cancercell, comprising (a) identifying a potential susceptibility to treatmentof a cancer cell with a procaspase activator compound; and (b) exposingsaid cancer cell to an effective amount of the procaspase activatorcompound. In an embodiment, the procaspase activator compound isselected from the group consisting of formula ZZ or subsets of compoundsof such formula, PAC-1, and Structure 5. In an embodiment, the method ofclaim 16 wherein said procaspase activator compound is capable ofactivating procaspase-3, procaspase-7, or both procaspase-3 andprocaspase-7.

In an embodiment, the invention provides a method of synthesizing PAC-1,comprising the steps of Scheme 1. In an embodiment, the inventionprovides a method of synthesizing Compound 5, comprising the steps ofScheme 1 with appropriate modification. In an embodiment, the inventionprovides a method of synthesizing compounds of the formula Z asdisclosed herein and as would be understood in the art.

In an embodiment, the invention provides compounds of the formula Z1,ZA1, ZC1 or ZZ1:

and salts thereof where variables are as defined above.

In specific embodiments of formulas Z1, ZA1, ZC1 and ZZ1, R₂X is OH. Inspecific specific embodiments of formulas Z1 and ZA1, both R₄ and R₅ areN. In specific embodiments of formulas Z1, ZA1, ZC1 and ZZ1, R₆ ishydrogen. In specific embodiments of formulas Z1, ZA1, ZC1 and ZZ1, R₃is allyl. In a specific embodiment of formulas Z1, ZA1, ZC1 and ZZ1, atleast one R or R₃ is a substituent other than hydrogen. In a specificembodiment of formulas Z1, ZA1, ZC1 and ZZ1, at least one R is asubstituent other than hydrogen. In a specific embodiment of formulasZ1, ZA1, ZC1 and ZZ1, R₂X is OH and R₃ is allyl. In specific embodimentsof formulas Z1, ZA1, ZC1 and ZZ1, one or two of Ra, Rb, Rc, Rd or Re arehalogens, C1-C3 alkyl or C1-C3 alkoxy groups and the remaining groupsare hydrogens. In specific embodiments of formulas Z1, ZA1, ZC1 and ZZ1,all of Ra, Rb, Rc, Rd, and Re are hydrogens.

In specific embodiments of GXX1, R₃ and R are all hydrogens. In specificembodiments of GXX1, Ra, Rb, Rc, Rd, and Re are all hydrogens. Inspecific embodiments of GXX1, n is 1. In specific embodiments of GXX1,R₆ is hydrogen.

In specific embodiments, the invention provides compounds of formulaDX1, DX2, DX3, DX4, DX5, DX6, DX7, DX8, DX9, DX10, DX11, DX12, DX13,DX14, DX15, DX16, or DX17. In specific embodiments, the inventionprovides compounds of formulas illustrated in FIG. 12 . In specificembodiments, the invention provides compounds of formulas FX1, FX2, FX3,FX4, FX5, FX6, FX7, FX8, and FX9.

In specific embodiments, the invention provides a compound of formulaGX1.

In an embodiment, the invention provides a therapeutic compositioncomprising one or more compounds of any of the formulas herein and foreach compound a pharmaceutically acceptable salt or ester thereof;wherein the compounds are present in the composition in an amount or ina combined amount effective for obtaining the desired therapeuticbenefit. The therapeutic compositions of this invention optionallyfurther comprise one or more pharmaceutically acceptable components, forexample carriers and excipients as known in the art.

In an embodiment, the invention provides a method of screening acandidate cancer patient for possible treatment with a procaspaseactivator by identifying an elevated level of a procaspase in thecandidate, comprising obtaining a cell or tissue test sample from thecandidate, assessing the procaspase level in the test sample, anddetermining whether the procaspase level is elevated in the test samplerelative to a reference level, thereby screening a candidate cancerpatient for possible treatment with a procaspase activator. In anembodiment, the procaspase is selected from the group consisting ofprocaspase-2, -3, -6-, -7, -8, and -9. In a particular embodiment, theprocaspase is procaspase-3.

In an embodiment, an elevated level of the test sample is at least about2-fold greater than the reference level. In an embodiment, an elevatedlevel of the test sample is at least about 4-fold greater than thereference level. In an embodiment, the reference level is from a secondtest sample from the same patient. In an embodiment, the reference levelis from a normal cell or tissue sample. The reference level can be froma cell line, such as a cancer cell line or a normal cell line. In anembodiment, the reference level is an absolute threshold amount. SeeSvingen, P. A. et al., Clin. Cancer Res. 10:6807-6820, which describesvarious amounts of levels of procaspases including numbers of moleculesper cell.

In an embodiment, the invention provides a method of inducing apoptosisin a cell, comprising administering to said cell a compound of theinvention. In an embodiment, the cell is a cancer cell. In anembodiment, the compound has structural formula Z, ZA, ZB, ZC, ZD or ZZ.

In an embodiment, the invention provides a method of inducing death in acancer cell, comprising administering to said cancer cell a compoundcapable of activating a procaspase molecule of said cancer cell. In anembodiment, the procaspase is one or more of procaspase-3 andprocaspase-7. In a preferred embodiment, the procaspase is procaspase 3.In an embodiment, the compound has structural formula Z, ZA, ZB, ZC, ZDor ZZ.

In an embodiment, the invention provides a medicament comprising one ormore compounds of formulas Z, ZA, ZB, ZC, ZD, or ZZ as well as a methodfor making a medicament comprising such compounds. More specifically,the medicament further comprising a pharmaceutically acceptable carriersuitable for a selected means of administration of the medicament. In amore specific method of making the medicament, one or more compounds ofthe recited formulas are combined with the selected pharmaceuticallyacceptable carrier.

In an embodiment, the invention provides compositions and methods wherea compound of the composition or method is not a compound disclosed in:U.S. Provisional Application Ser. 60/684,807 filed May 26, 2005; U.S.Provisional Application Ser. 60/743,878 filed Mar. 28, 2006; U.S. patentapplication Ser. No. 11/420,425 filed May 25, 2006 (published as US20070049602, Mar. 1, 2007); PCT International Application Serial PCT/USSer. No. 06/020,910 filed May 26, 2006 (published as WO2006/128173, 30Nov. 2006). In an embodiment herein, said compound is not a compound offormula is of formula ZZX:

wherein n=1 or 2; R, independently of other R, is hydrogen, halogen,allyl, or short alkyl; R2=hydrogen, short alkyl, ester, or other moietythat is removable under physiological conditions; R3=hydrogen, halogen,alkyl, haloalkyl, allyl, alkenyl, alkenol, alkanol, or haloalkenyl; R4and R5 are N; or R4=N and R5=C; or R4 and R5=C; and A=oxygen or sulfur.

BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1A and 1B. A) In vitro activation of procaspase-3 and activecaspase-3 by PAC-1. PAC-1 activates procaspase-3 with an EC₅₀=0.22 μM.Error bars represent standard deviations from the mean. B) Cleavage ofprocaspase-3 to active caspase-3 as induced by PAC-1. Procaspase-3 wasrecombinantly expressed in E. coli with an N-terminal His-6 tag (SEQ IDNO: 29) and purified. Immunoblotting was performed with an anti-His-6(“His-6” disclosed as SEQ ID NO: 29) antibody. In the absence of PAC-1,no maturation of procaspase-3 is observed. In the presence of 100 μMPAC-1, cleavage to generate the p19 fragment is observed within 1 hour,and >50% cleavage is observed after 4 hours.

FIGS. 2A, 2B, and 2C. A) Activation of mutants in the “safety catch”region of procaspase-3 by PAC-1. PAC-1 has an EC₅₀ for activation of0.22 μM on wild type procaspase-3 (DDD), and corresponding EC₅₀ valuesof 2.77 μM (DAD), 113 μM (DDA), and 131 μM (ADD) for certain mutants. B)PAC-1 activates procaspase-7 with an EC₅₀ of 4.5 μM. C) Dependence ofPAC-1 activation of procaspase-3 on pH. At low pH the safety catch is“off”, and procaspase-3 is essentially maximally activated. Error barsrepresent standard deviations from the mean.

FIGS. 3A and 3B. PAC-1 induces apoptosis in HL-60 cells. A)Phosphatidylserine exposure (as measured by Annexin-V staining) after a20 hour treatment with 100 μM PAC-1. B) Chromatin condensation asvisualized by Hoescht staining after a 20 hour treatment with 100 μMPAC-1.

FIG. 4A-E. A) Mitochondrial membrane depolarization (MMP) and caspase-3like activity in HL-60 cells treated with 10 μM etoposide. B)Mitochondrial membrane depolarization (MMP) and caspase-3 like activityin HL-60 cells treated with 100 μM PAC-1. C) PAC-1 treatment (100 μM)induces a rapid decrease in cellular PARP activity in HL-60 cells,consistent with an immediate activation of cellular caspase-3/-7. Incontrast, etoposide (10 μM) treated cells show a decrease in PARPactivity at much later time points. D) PAC-1 induces cell death in aprocaspase-3 dependent manner. For a number of diverse cancer celllines, the procaspase-3 levels were determined (by flow cytometry) andthe IC₅₀ of PAC-1 was measured (R2=0.9822). PAC-1 is quite potent(IC₅₀=0.35 μM) in the NCI-H226 lung cancer cell line known to have highlevels of procaspase-3, but markedly less potent in normal white bloodcells derived from the bone marrow of a healthy human donor.

FIG. 5A illustrates relative procaspase-3 levels in normal and cancerouscells from several patients.

FIG. 5B illustrates IC₅₀ levels for PAC-1 in a variety of cell typeshaving a range of relative procaspase-3 levels.

FIG. 5C illustrates the effect of treating animals with PAC-1 onoutcomes of tumor growth.

FIG. 5D illustrates the effect of oral treatment of animals with PAC-1on outcomes of tumor growth.

FIG. 5E illustrates results of progression of cancer in a lung cancermodel for control, PAC-1, and gefitinib (Iressa™; AstraZeneca) treatmentgroups. Tumor cells were injected into mice by i.v. administration;Iressa and PAC-1 were given orally at 100 mg/kg.

FIG. 6A illustrates relative procaspase-3 levels in normal and cancerouscells of three patients.

FIG. 6B illustrates the sensitivity of normal and cancerous cells fromPatient 3 to treatment with PAC-1.

FIG. 7 illustrates results of administering PAC-1 intraperitoneally inthe context of a mouse model of lung cancer.

FIGS. 8A and 8B illustrate structures for compounds of PAC-1 derivativesand a combinatorial library.

FIG. 9 illustrates a nucleotide sequence (SEQ ID NO: 1) for Homo sapienscaspase 3, apoptosis-related cysteine peptidase (CASP3), transcriptvariant alpha, mRNA (Accession No. NM_004346; 2689 bp mRNA linear;obtained from ncbi.nlm.nih.gov/entrez).

FIG. 10 illustrates a nucleotide sequence (SEQ ID NO: 16) for Homosapiens caspase 7, apoptosis-related cysteine peptidase (CASP7),transcript variant alpha, mRNA (Accession No. NM_001227; 2605 bp; mRNAlinear; obtained from ncbi.nlm.nih.gov/entrez).

FIG. 11 illustrates structures for compounds designated DX1-DX17 (see,e.g., Examples 9 and 10).

FIG. 12 illustrates activity levels (IC₅₀ values) next to structures ofcompounds DX1-17 from apoptosis induction assays using HL-60 cells.

FIG. 13 illustrates results of testing certain compounds for the abilityto effect activation of procaspase-3.

FIG. 14 illustrates the structures of certain compounds includingFX1-FX9 and GX1.

FIG. 15 illustrates results from activity testing of various compoundsin the series DX, FX, and GX. Test conditions used 2.5 μM procaspase-3(D₃A) with the indicated test compound at 100 μM (filled columns); andfurther with 10 μM zinc (open columns).

FIG. 16 illustrates results from activity testing of compounds in theseries DX and FX, plotted as percent activity versus compoundconcentration.

DETAILED DESCRIPTION OF THE INVENTION

In general, the terms and phrases used herein have their art-recognizedmeaning, which can be found by reference to standard texts, journalreferences and contexts known to those skilled in the art.

The following abbreviations are applicable. IAP, inhibitor of apoptosis;PAC-1, procaspase activating compound 1; PARP, Poly(ADP-ribose)polymerase.

The following definitions are provided to clarify their specific use inthe context of the invention.

When used herein, the term “chemotherapeutic agent” refers to anysubstance capable of reducing or preventing the growth, proliferation,or spread of a cancer cell, a population of cancer cells, tumor, orother malignant tissue. The term is intended also to encompass anyantitumor or anticancer agent.

When used herein, the term “effective amount” is intended to encompasscontexts such as a pharmaceutically effective amount or therapeuticallyeffective amount. For example, in embodiments the amount is capable ofachieving a beneficial state, beneficial outcome, functional activity ina screening assay, or improvement of a clinical condition.

When used herein, the term “cancer cell” is intended to encompassdefinitions as broadly understood in the art. In an embodiment, the termrefers to an abnormally regulated cell that can contribute to a clinicalcondition of cancer in a human or animal. In an embodiment, the term canrefer to a cultured cell line or a cell within or derived from a humanor animal body. A cancer cell can be of a wide variety of differentiatedcell, tissue, or organ types as is understood in the art.

The term “alkyl” refers to a mono-radical branched or unbranchedsaturated hydrocarbon chain preferably having from 1 to 22 carbon atomsand to cycloalkyl groups having one or more rings having 3 to 22 carbonatoms. Short alkyl groups are those having 1 to 6 carbon atoms includingmethyl, ethyl, propyl, butyl, pentyl and hexyl groups, including allisomers thereof. Long alkyl groups are those having 8-22 carbon atomsand preferably those having 12-22 carbon atoms as well as those having12-20 and those having 16-18 carbon atoms.

The term “cycloalkyl” refers to cyclic alkyl groups of from 3 to 22carbon atoms having a single cyclic ring or multiple condensed rings.Cycloalkyl groups include those having 3-8 member rings and those having5 and 6 member rings. Cycloalkyl groups include, by way of example,single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl,cyclohexyl, cyclooctyl, and the like, or multiple ring structures suchas adamantanyl, and the like.

The term “alkenyl” refers to a monoradical of a branched or unbranchedunsaturated hydrocarbon group preferably having from 2 to 22 carbonatoms and to cycloalkenyl groups having one or more rings having 3 to 22carbon atoms wherein at least one ring contains a double bond. Alkenylgroups may contain one or more double bonds (C═C) which may beconjugated. Preferred alkenyl groups are those having 1 or 2 doublebonds. Short alkenyl groups are those having 2 to 6 carbon atomsincluding ethylene (vinyl) propylene, butylene, pentylene and hexylenegroups, including all isomers thereof. Long alkenyl groups are thosehaving 8-22 carbon atoms and preferably those having 12-22 carbon atomsas well as those having 12-20 carbon atoms and those having 16-18 carbonatoms. The term “cycloalkenyl” refers to cyclic alkenyl groups of from 3to 22 carbon atoms having a single cyclic ring or multiple condensedrings in which at least one ring contains a double bond (C═C).Cycloalkenyl groups include, by way of example, single ring structuressuch as cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclooctenyl,cylcooctadienyl and cyclooctatrienyl. The term allyl refers to thealkenyl group —CH₂—CH═CH₂.

The term “alkynyl” refers to a mono-radical of an unsaturatedhydrocarbon preferably having from 2 to 22 carbon atoms and having oneor more triple bonds (C≡C). Alkynyl groups include ethynyl, propargyl,and the like. Short alkynyl groups are those having 2 to 6 carbon atoms,including all isomers thereof. Long alkynyl groups are those having 8-22carbon atoms and preferably those having 12-22 carbon atoms as well asthose having 12-20 carbon atoms and those having 16-18 carbon atoms.

The term “aryl” refers to a group containing an unsaturated aromaticcarbocyclic group of from 6 to 22 carbon atoms having a single ring(e.g., phenyl), one or more rings (e.g., biphenyl) or multiple condensed(fused) rings, wherein at least one ring is aromatic (e.g., naphthyl,dihydrophenanthrenyl, fluorenyl, or anthryl). Aryls include phenyl,naphthyl and the like. Aryl groups may contain portions that are alkyl,alkenyl or akynyl in addition to the unsaturated aromatic ring(s). Theterm “alkaryl” refers to the aryl groups containing alkyl portions,i.e., -alkylene-aryl and -substituted alkylene-aryly. Such alkarylgroups are exemplified by benzyl (—CH₂-phenyl), phenethyl and the like.

Alkyl, alkenyl, alkynyl and aryl groups are optionally substituted asdescribed herein (the term(s) can include substituted variations) andmay contain 1-8 non-hydrogen substituents dependent upon the number ofcarbon atoms in the group and the degree of unsaturation of the group.All such variable as described herein can be unsubstituted (in which anyvariables groups that can be hydrogen are hydrogen) or substituted withone or more non-hydrogen substituents selected from halogen, includingfluorine, chlorine, bromine or iodine, C1-C3 haloalkyl, hydroxyl (OH),thiol (HS—), C1-C6 alkyl, C1-C3 alkyl, C1-C6 alkoxy, C1-C3 alkoxy,phenyl, benzyl, alkenyl, C2-C4 alkenyl, alkynyl, C2-C4 alkynyl, —NH₂,—NR′H, —NR′R″, R′CO—, R′R″NCO—, R′CO—NH—, or R′CO—NR″—, where R′ and R″are C1-C6 alkyl, C1-C3 alkyl or phenyl.

The term “amino” refers to the group —NH₂ or to the group —NR′R″ whereeach R′ and R″ is independently selected from the group consisting ofhydrogen, alkyl or aryl groups.

Haloalkyl” refers to alkyl as defined herein substituted by one or morehalo groups as defined herein, which may be the same or different.Representative haloalkyl groups include, by way of example,trifluoromethyl, 3-fluorododecyl, 12,12,12-trifluorododecyl,2-bromooctyl, 3-bromo-6-chloroheptyl, and the like.

The term “heteroaryl” refers to an aromatic group of from 2 to 22 carbonatoms having 1 to 4 heteroatoms selected from oxygen, nitrogen andsulfur within at least one ring (if there is more than one ring).Heteroaryl groups may be optionally substituted. Heteroaryl groupsinclude among others those having 5 and 6-member rings and those havingone or two nitrogen atoms in the ring, those having one or two oxygensin the ring as well as those having one or two sulfurs in the ring.

The term “heterocycle” or “heterocyclic” refers to a mono-radicalsaturated or unsaturated group having a single ring or multiplecondensed rings, from 2-22 carbon atoms and from 1 to 6 hetero atoms,preferably 1 to 4 heteroatoms, selected from nitrogen, sulfur,phosphorus, and/or oxygen within at least one ring. Heterocyclic groupsmay be substituted. Rings preferably have 3-10 members and morespecifically have 5 or 6 members.

The term “ester” refers to chemical entities as understood in the artand in particular can include groups of the form (RCO—).

As to any of the above groups which contain one or more substituents, itis understood, that such groups do not contain any substitution orsubstitution patterns which are sterically impractical and/orsynthetically non-feasible. The compounds of this invention include allnovel stereochemical isomers arising from the substitution of disclosedcompounds.

In an embodiment, the invention provides compounds of the formula Zexcluding PAC-1, wherein the structure of PAC-1 is:

In an embodiment, the invention provides a compound of compound 5, whichis:

In an embodiment, the invention provides a compound of formula Z otherthan compound 5.

In an embodiment, the invention provides a compound having the formulaZ2:

wherein R₁ and R₂ independently represent substitution on the indicatedrings with one or more hydrogen, halogen, alkyl, allyl, haloalkyl,alkenyl, alkenol, alkanol, or haloalkenyl. In an embodiment, R₁ and R₂independently represent substitution on the indicated rings with one ormore hydrogen, halogen, allyl, or C1-C3 alkyl.

In an embodiment, the invention provides a compound selected from thegroup consisting of a PAC-1 derivative combinatorial library comprisinga hydrazide compound combined with an aldehyde compound. In anembodiment, the hydrazide compound is selected from the group consistingof hydrazides generated from AX compounds described herein.

In an embodiment, the aldehyde compound is selected from the groupconsisting of BX compounds described herein. In an embodiment, thehydrazide compound is selected from the group consisting of AX compoundsdescribed herein and the aldehyde compound is selected from the groupconsisting of BX compounds described herein.

In an embodiment, the invention provides a method of synthesizing aPAC-1 derivative compound comprising providing a hydrazide compound,providing an aldehyde compound, and reacting the hydrazide compound withthe aldehyde compound, thereby synthesizing a PAC-1 derivative compound.

In an embodiment, the hydrazide compound has the formula ZZ3:

where R₁ represents substitution on the indicated ring of one or more Rgroups as defined in formula Z.

In an embodiment, the aldehyde compound has the formula ZZ4:

where R₂ represents substitution on the indicated ring of one or more R₃or R groups as defined in formula Z.

In an embodiment, the hydrazide compound has the formula ZZ3 and thealdehyde compound has the formula ZZ4.

In an embodiment, the invention provides a compound selected from thegroup consisting of: L01R06, L02R03, L02R06, L08R06, L09R03, L09R06, andL09R08.

In an embodiment, a composition of the invention is a chemotherapeuticagent.

In an embodiment, the invention provides compounds and methods involvingeffective concentrations preferably from about 10 nM to about 100 μM ofthe disclosed structural formulas. In another preferred embodiment, theeffective concentrations are from about 200 nM to about 5 μM. In anembodiment, the effective concentration is considered to be a value suchas a 50% activity concentration in a direct procaspase activation assay,in a cell apoptosis induction assay, or in an animal clinicaltherapeutic assessment. In a preferred embodiment, such value is lessthan about 200 μM. In a preferred embodiment, the value is less thanabout 10 μM.

Compounds of the invention and compounds useful in the methods of thisinvention include those of the disclosed formulas and salts and estersof those compounds, including preferably pharmaceutically-acceptablesalts and esters.

In an embodiment, the invention provides prodrug forms of compositions.Prodrugs of the compounds of the invention are useful in the methods ofthis invention. Any compound that will be converted in vivo to provide abiologically, pharmaceutically or therapeutically active form of acompound of the invention is a prodrug. Various examples and forms ofprodrugs are well known in the art. A biomolecule such as a precursorprotein or precursor nucleic acid can be a prodrug. Examples of prodrugsare found, inter alia, in Design of Prodrugs, edited by H. Bundgaard(Elsevier, 1985), Methods in Enzymology, Vol. 42, at pp. 309-396, editedby K. Widder et. al. (Academic Press, 1985); A Textbook of Drug Designand Development, edited by Krosgaard-Larsen and H. Bundgaard, Chapter 5,“Design and Application of Prodrugs,” by H. Bundgaard, at pp. 113-191,1991); H. Bundgaard, Advanced Drug Delivery Reviews, Vol. 8, p. 1-38(1992); H. Bundgaard, et al., Journal of Pharmaceutical Sciences, Vol.77, p. 285 (1988); and Nogrady (1985) Medicinal Chemistry A BiochemicalApproach, Oxford University Press, New York, pages 388-392).

In an embodiment, a composition of the invention is in a form that isisolated or purified. It is recognized that regardless of the ultimatecorrectness of any mechanistic explanation or hypothesis believed ordisclosed herein, an embodiment of the invention can nonetheless beoperative and useful.

When a group of substituents is disclosed herein, it is understood thatall individual members of that group and all subgroups, including anyisomers and enantiomers of the group members, are disclosed separately.When a Markush group or other grouping is used herein, all individualmembers of the group and all combinations and sub-combinations possibleof the group are intended to be individually included in the disclosure.It is intended that any one or more members of any Markush group orlisting provided in the specification can be excluded from the inventionif desired. When a compound is described herein such that a particularisomer or enantiomer of the compound is not specified, for example, in aformula or in a chemical name, that description is intended to includeeach isomers and enantiomer of the compound described individual or inany combination. Additionally, unless otherwise specified, all isotopicvariants of compounds disclosed herein are intended to be encompassed bythe disclosure. For example, it will be understood that any one or morehydrogens in a molecule disclosed can be replaced with deuterium ortritium. Isotopic variants of a molecule are generally useful asstandards in assays for the molecule and in chemical and biologicalresearch related to the molecule or its use. Specific names of compoundsare intended to be exemplary, as it is known that one of ordinary skillin the art can name the same compounds differently.

Molecules disclosed herein may contain one or more ionizable groups[groups from which a proton can be removed (e.g., —OH, —COOH, etc.) oradded (e.g., amines) or which can be quaternized (e.g., amines)]. Allpossible ionic forms of such molecules and salts thereof are intended tobe included individually in the disclosure herein. With regard to saltsof the compounds herein, one of ordinary skill in the art can selectfrom among a wide variety of available counterions those that areappropriate for preparation of salts of this invention for a givenapplication. For example, in general any anions can be employed in theformation of salts of compounds herein; e.g. halide, sulfate,carboxylate, acetate, phosphate, nitrate, trifluoroacetate, glycolate,pyruvate, oxalate, malate, succinate, fumarate, tartrate, citrate,benzoate, methanesulfonate, ethanesulfonate, p-toluenesulfonate,salicylate and others.

Compounds of the present invention, and salts or esters thereof, mayexist in their tautomeric form, in which hydrogen atoms are transposedto other parts of the molecules and the chemical bonds between the atomsof the molecules are consequently rearranged. It should be understoodthat all tautomeric forms, insofar as they may exist, are includedwithin the invention. Additionally, the compounds may have trans and cisisomers and may contain one or more chiral centers, therefore existingin enantiomeric and diastereomeric forms. The invention can encompassall such isomers, individual enantiomers, as well as mixtures of cis andtrans isomers, mixtures of diastereomers; non-racemic and racemicmixtures of enantiomers (optical isomers); and the foregoing mixturesenriched for one or more forms; except as stated otherwise herein. Whenno specific mention is made of the configuration (cis, trans or R or S)of a compound (or of an asymmetric carbon), then any one of the isomersor a mixture of more than one isomer is intended. The processes forpreparation can use racemates, enantiomers, or diastereomers as startingmaterials. When enantiomeric or diastereomeric products are prepared,they can be separated by conventional methods, for example, bychromatographic or fractional crystallization. The inventive compoundsmay be in the free or hydrate form.

Every formulation or combination of components described or exemplifiedherein can be used to practice the invention, unless otherwise stated.

Whenever a range is described in the present application, for example, atemperature range, a time range, or a composition or concentrationrange, all intermediate ranges and subranges, as well as all individualvalues included in the ranges given are intended to be included in thedisclosure.

Information in any references disclosed herein can in some casesindicate the state of the art, for example for patent documents as oftheir effective filing dates; it is intended that such information canbe employed herein, if needed, to exclude specific embodiments that areactually found to be in the prior art. For example, when a compound isdisclosed and/or claimed, it should be understood that compoundsqualifying as prior art with regard to the present invention, includingcompounds for which an enabling disclosure is provided in thereferences, are not intended to be included in the composition of matterclaims herein.

Some references provided herein are incorporated by reference to providedetails concerning sources of starting materials, additional startingmaterials, additional reagents, additional methods of synthesis,additional methods of analysis, and additional uses of the invention.One of ordinary skill in the art will appreciate that startingmaterials, reagents, solid substrates, synthetic methods, purificationmethods, and analytical methods other than those specificallyexemplified can be employed in the practice of the invention based onknowledge in the art and without resort to undue experimentation. Theinvention may be further understood by the following non-limitingexamples.

Example 1. Procaspase Activating Compounds

Mutation or aberrant expression of proteins in the apoptotic cascade isa frequent hallmark of cancer. These changes can prevent proapoptoticsignals from being transmitted to the executioner caspases, thuspreventing apoptotic cell death and allowing cellular proliferation.Caspase-3 and caspase-7 are key executioner caspases, existing asinactive zymogens that are activated by upstream signals. Importantly,expression levels of procaspase-3 are significantly higher in certaincancerous cells relative to non-cancerous controls. Here we report theidentification of small molecules that directly activate procaspase-3 toactive caspase-3. A particular compound, PAC-1, effects activation invitro with an EC₅₀ on the order of 220 nanomolar and induces apoptosisin a multitude of cancerous cell lines.

In contrast to many known anti-cancer drugs, cells treated with PAC-1show an immediate activation of procaspase-3, and the toxicity of PAC-1is shown to be directly proportional to the amount of procaspase-3contained in a cell. Thus PAC-1 directly activates procaspase-3 tocaspase-3 in vivo, allowing this compound to induce apoptosis even incells that have defective apoptotic machinery. PAC-1 is the first smallmolecule known to directly activate procaspase-3; the direct activationof executioner caspases is a novel anti-cancer strategy that may provebeneficial in a variety of cancers, including the many cancers in whichprocaspase-3 is upregulated.

A collection of about 20,000 structurally diverse small molecules wasscreened for the ability to activate procaspase-3 in vitro. Procaspase-3was expressed and purified in E. coli (Roy et al., 2001). Procaspase-3(at a concentration of 50 ng/mL) was added to the wells of a 384-wellplate, and the compounds were added to a final concentration ofapproximately 40 μM. Each plate was then incubated for two hours at 37°C., after which the caspase-3 peptidic substrateAc-Asp-Glu-Val-Asp-p-nitroanilide (Ac-DEVD-pNa) (SEQ ID NO: 28) wasadded to a concentration of 200 μM. The formation of the p-nitroanilinechromophore was followed at 405 nm over the course of two hours.

Of the compounds evaluated, four induced a significant increase overbackground in the hydrolysis of the peptidic caspase-3 substrate. Ofthose four, one showed a strong dose-dependent effect on in vitroprocaspase-3 activation. As shown in FIG. 1A, this first procaspaseactivating compound (PAC-1) gives half-maximal activation ofprocaspase-3 at a concentration of 0.22 μM. This compound is not simplyincreasing the activity of caspase-3 itself, as it has no effect on thecatalytic activity of the fully processed caspase-3 enzyme (FIG. 1A).

Procaspase-3 has an N-terminal pro domain (residues 1-28), followed by alarge subunit (17 kDa) and a small subunit (12 kDa) that are separatedby an intersubunit linker (Pop et al., 2003). In vivo, two procaspase-3monomers assemble to form a catalytically inactive homodimer that can beactivated by cleavage at D175 in the intersubunit linker. The preciserole of the pro domain is unclear, and it has been shown that cleavagein the intersubunit region alone is sufficient for full catalyticactivity (Stennicke, H. R. et al., 1998). Although procaspase-3 iscatalytically competent, it is highly resistant to autoactivation due tothe presence of the 12-amino acid safety catch; however, when the safetycatch is mutated significant autoactivation of procaspase-3 is observed(Roy et al., 2001). Compounds that interact with this importantregulatory region or at other positions can allow the autoactivation ofprocaspase-3.

To directly assess the ability of PAC-1 to catalyze the autoactivationof procaspase-3, the procaspase-3 protein was incubated with 100 μM ofPAC-1 for time points ranging from one to five hours. As shown by theWestern blot in FIG. 1B, PAC-1 induces the cleavage of procaspase-3 in atime-dependent fashion, with >50% processing observed after 4 hours. Incontrast, procaspase-3 incubated in buffer shows virtually noautoactivation over that same time span. In an attempt to pinpoint theregion of procaspase-3 with which PAC-1 is interacting, alaninesubstitutions were made in the key aspartic acid triad in the safetycatch region, residues Asp179, Asp180 and Asp181. Mutations at thesepositions all dramatically decreased the ability of PAC-1 to activateprocaspase-3, with certain mutations more detrimental to activation ofprocaspase-3 by PAC-1 (FIG. 2A).

Like caspase-3, caspase-7 also exists as an inactive zymogen that isactivated by proteolysis. Caspase-3 and caspase-7 are both executionercaspases and have considerable sequence and structural homology(Denault, J.-B. et al., 2003). Procaspase-7 may also have a similarsafety catch region, although it has only two aspartic acids in the keytriad (Asp-Thr-Asp), instead of three. As indicated by the data in FIG.2B, PAC-1 can also activate procaspase-7, although in a less efficientmanner than its activation of procaspase-3 (EC₅₀ of 4.5 μM versus 0.22μM for procaspase-3 activation). The potency of procaspase-7 activationby PAC-1 is similar to its effect on the Asp-Ala-Asp mutant ofprocaspase-3 (EC₅₀=2.77 μM). The effect of PAC-1 is abolished at low pHvalues where procaspase-3 undergoes rapid autoactivation (FIG. 2C).

The ability for a small molecule that activates procaspase-3 to induceapoptosis in human cell lines was tested, and PAC-1 was found to induceapoptosis in a variety of cancer cell lines. In HL-60 cells addition ofPAC-1 leads to considerable phosphatidylserine exposure on the cellmembrane accompanied by significant chromatin condensation (FIGS. 3A and3B). In addition, the compound induces cleavage of PARP-1 (as assessedby an in vivo PARP activity assay; Putt K S et al., 2005) and causesmitochondrial membrane depolarization (see below). Significant cellularblebbing was also observed by microscopy. Furthermore, the toxicity ofPAC-1 could be abolished in the presence of the caspase inhibitorz-VAD-fmk (data not shown; see Slee et al., 1996).

If PAC-1 is indeed inducing apoptosis via direct activation ofprocaspase-3, the time course of apoptotic events should be alteredrelative to that observed with standard proapoptotic agents. Etoposideis well known to induce apoptosis through the intrinsic pathway; thus,mitochondrial membrane depolarization is followed by procaspase-3activation in etoposide-treated cells. Indeed, in HL-60 cells treatedwith 10 μM etoposide, mitochondrial membrane depolarization is observed,followed by detection of caspase-3-like activity (FIG. 4A).

In contrast, treatment of cells with PAC-1 gives a markedly differentresult. With PAC-1, the first observed biochemical hallmark of apoptosisis caspase-3-like enzymatic activity. This activity is noted withinminutes of compound addition, and 50% activation takes place in justover 2 hours and well before any significant mitochondrial membranedepolarization (FIG. 4B). In addition, PARP activity is rapidly reducedin cells treated with PAC-1, whereas this reduction is observed at latertime points in etoposide treated cells (FIG. 4C). Control experimentsshow that PAC-1 does not directly inhibit enzymatic activity of PARP-1.In the typical sequence of apoptotic events, the mitochondrial membranedepolarizes, caspases are activated, and caspase substrates (such asPARP-1) are cleaved. The observation that cells treated with PAC-1 showa rapid activation of caspase-3/-7 (before mitochondrial membranedepolarization) and a rapid cleavage of a caspase substrate isindicative of this compound exerting its cellular toxicity through thedirect activation of procaspase-3.

To further define the potency of PAC-1, the ability of this compound toinduce cell death in cancer cell lines with varying levels ofprocaspase-3 was assessed. A determination was made of the amount ofprocaspase-3 present in multiple cancer cell lines (leukemia, lymphoma,melanoma, neuroblastoma, breast cancer, lung cancer and renal cancer)and in the white blood cells isolated from the bone marrow of a healthydonor. The IC₅₀ values for cell death induction were obtained for PAC-1in these cell lines. The combined data shows a strong correlationbetween cellular concentration of procaspase-3 and sensitivity to PAC-1(FIG. 4D). Notably, the white blood cells derived from the bone marrowof a healthy human donor are among those with the lowest amount ofprocaspase-3, and PAC-1 is comparatively less toxic to these cells.PAC-1 is most potent versus the lung cancer cell line NCI-H226, with anIC₅₀ of 0.35 μM. In accordance with data in the literature (Svingen etal., 2004), we found this cell line to have a concentration ofprocaspase-3 that is greater than five times that of the non-cancerouscontrol.

In contrast to these experiments with PAC-1, etoposide showed no suchcorrelation between potency in cell culture and cellular levels ofprocaspase-3. For instance, etoposide was ineffective (IC₅₀>50 μM) ininducing death in three of the melanoma cell lines (UACC-62, CRL-1872,and B16-F10), the breast cancer cell line (Hs 578t), and the lung cancercell line (NCI-H226); these cell lines have procaspase-3 levels of 1.0,2.4, 1.9, 3.7, and 5.3, respectively. Etoposide was effective (IC₅₀<1μM) versus HL-60, U-937, SK-N-SH and PC-12, which have procaspase-3levels of 4.3, 4.0, 4.7, and 4.4, respectively. Thus, overall there isno correlation between procaspase-3 levels and IC₅₀ for etoposide.

Cancerous cells typically have a reduced sensitivity to proapoptoticsignals due to the mutation or aberrant expression of an assortment ofproteins in the apoptotic cascade. As such, many types of cancer arenotoriously resistant to not only the endogenous signals for apoptoticcell death, but also to chemotherapeutic agents that act through similarmechanisms. The paradoxical upregulation of procaspase-3 expressionlevels in certain cancers provides an opportunity to use this existingintracellular pool of protein to directly induce apoptosis, thusbypassing the often non-functional or compromised upstream portion ofthe cascade. Although procaspase-3 is notorious for its relativeinability to undergo autoactivation, it is dependent upon a 12-aminoacid safety catch to keep itself in the inactive state. PAC-1 inducesthe autoactivation of procaspase-3 in vitro, and this activation isgreatly diminished by mutation of the key tri-aspartate region of thesafety catch. This data is consistent with the notion that PAC-1 isdirectly interfering with the ability of the safety catch to maintainprocaspase-3 dormancy.

In cell culture, PAC-1 treatment induces rapid caspase-3-like activity.It is likely that the caspase-3 mediated cleavage of anti-apoptoticproteins (Bcl-2, Bcl-XL, etc.) then induces depolarization of themitochondrial membrane and amplifies apoptosis. Further, the potency ofPAC-1 toward a variety of cancer cell lines is directly proportional tothe concentration of procaspase-3 in the cell. It is worth noting thatseveral of the cell lines that PAC-1 is effective against have faultyapoptotic pathways that make them resistant to apoptosis; for instance,Apaf-1 expression is dramatically decreased in SK-MEL-5 cells, and Bcl-2is overexpressed in the NCI-H226 lung cancer cell line.

Data presented herein fully support the notion that procaspase-3activating compounds can be exceedingly effective against commoncancers. The effectiveness can be enhanced for situations in whichprocaspase-3 levels are aberrantly high.

Assessment of procaspase-3 levels in cancer biopsies can be simple andrapid; as such, the potential effectiveness of a compound such as PAC-1can be assessed a priori with a high degree of accuracy. Procaspase-3activators and methods herein thus provide personalized medicinestrategies that can be preferential to therapies that rely on generalcytotoxins in the realm of anti-cancer treatments.

Materials and Methods

Materials: Ni-NTA resin and anti-Penta His Alexa Fluor 647 antibody waspurchased from Qiagen (Valencia, Calif.). Bradford dye was purchasedfrom Bio-Rad (Hercules, Calif.). Pin transfer devices were purchasedfrom V & P Scientific (San Diego, Calif.). The reagent z-vad-fmk waspurchased from Calbiochem (San Diego, Calif.). Rosetta E. coli waspurchased from Novagen (Madison, Wis.). Anti-caspase-3 antibody waspurchased from Sigma (St. Louis, Mo.). Annexin V Alexa Fluor 488conjugate, JC-9, and propidium iodide were purchased from MolecularProbes (Eugene, Oreg.). IPTG and MTS/PMS CellTiter 96 Cell ProliferationAssay reagent were purchased from Promega (Madison, Wis.). Fetal BovineSerum was purchased from Biomeda (Foster City, Calif.). 96 and 384-wellmicrotiter plates, microscope slides, microscope coverslips, horse serumand all other reagents were purchased from Fisher (Chicago, Ill.).

Methods: Cell Culture Conditions. U-937, HL-60, CRL-1872, ACHN,NCI-H226, SK-MEL-5 and UACC-62 cells were grown in RPMI 1640 mediasupplemented with 10% FBS. SK-N-SH, B16-F10 and Hs 578t cells were grownin Eagle's minimal essential medium with Earle's BSS, 1.5 g/L sodiumbicarbonate and supplemented with 10% FBS. PC-12 cells were grown inRPMI 1640 media supplemented with 5% FBS and 10% horse serum. Human bonemarrow was grown in IDMEM supplemented with 40% FBS. All cell lines wereincubated at 37° C. in a 5% CO₂, 95% air atmosphere. U-937 and HL-60cells were split every two to three days as needed. Human bone marrowwas thawed from frozen stock and immediately diluted and used forexperiments. All other cells were split when they reached approximately80% confluency.

Protein Expression and Purification. 1 mL of an overnight culture ofRosetta E. coli containing the procaspase-3 or procaspase-7 expressionplasmid was seeded into 1 L of LB media containing proper antibiotic.Cells were induced with 1 mM IPTG for 30 minutes. Cells were then spundown and re-suspended in NTA binding buffer (150 mM NaCl, 50 mM Tris, 10mM Imidazole, pH 7.9). The cells were lysed by passing twice through aFrench press. The cell lysate was then spun at 14,000×g for 30 min. Thesupernatant was decanted and 1 mL of nickel-NTA resin was added. Thecell lysate was incubated for 1 hour at 4° C. The resin was loaded on acolumn, washed with 10 mL NTA binding buffer followed by 10 mL NTA washbuffer (150 mM NaCl, 50 mM Tris, 20 mM Imidazole, pH 7.9). The proteinswere eluted in 1 mL fractions with 10 mL of NTA elution buffer (150 mMNaCl, 50 mM Tris, 250 mM Imidazole, pH 7.9). Fractions containingprotein were pooled and the amount of protein was determined using theBradford assay.

Library Screen. Isolated procaspase-3 was diluted to 50 ng/mL in caspaseassay buffer (50 mM HEPES, 100 mM NaCl, 10 mM DTT, 0.1 mM EDTA, 0.1%CHAPS and 10% glycerol, pH 7.4). 45 μL of the procaspase-3 solution wasadded to each well of a Nunc 384-well flat bottom microtiter plate.Approximately 20,000 compounds were screened. About 6,000 of thecompounds were collected from various sources within the department ofchemistry at the University of Illinois; their structures are availableat: http://www.scs.uiuc.edu/˜phgroup/comcollections.html. The otherapproximately 14,000 compounds were purchased from ChembridgeCorporation (San Diego, Calif.). PAC-1 was a member of the compoundspurchased from Chembridge Corporation.

The compounds, made up as 10 mM stock solutions in DMSO, weretransferred into the wells using a 384-pin transfer apparatus thattransfers 0.2 μL of compound. This yielded a final compoundconcentration of about 40 μM. Controls were performed in which only DMSO(containing no compound) was pin-transferred. The plates were thenincubated for 2 hours at 37° C. 5 μL of a 2 mM solution of Ac-DEVD-pNA(N-acetyl-ASP-Glu-Val-Asp-p-nitroanilide) (SEQ ID NO: 28) in caspaseassay buffer was added to each well. The plate was then read every 2minutes at 405 nm for 2 hours in a Spectra Max Plus 384 plate reader(Molecular Devices, Sunnyvale Calif.). The slope of the linear portionfor each well was used to determine the activity of caspase-3.

Activation curves. The dose dependence of procaspase-3 activators wasdetermined by adding various concentrations of compound to 90 μL of a 50ng/mL procaspase-3, active caspase-3, procaspase-7 or active caspase-7in caspase assay buffer in a 96-well plate. The plate was then incubatedfor 12 hours at 37° C. 10 μL of a 2 mM solution of Ac-DEVD-pNA (SEQ IDNO: 28) in caspase assay buffer was then added to each well. The platewas read every 2 minutes at 405 nm for 2 hours in a Spectra Max Plus 384well plate reader. The slope of the linear portion for each well wasdetermined and the fold increase in activation from non-treated controlwells was calculated.

PAC-1 activation gel. Procaspase-3 was expressed and isolated exactly asabove. Procaspase-3 was diluted to about 50 μg/mL in caspase assaybuffer. The procaspase-3 was then incubated in the presence or absenceof 100 μM PAC-1 for varying times at 37° C. After this incubation, anequal volume of load buffer (150 mM NaCl, 50 mM Tris, 2% SDS, 20%glycerol, pH 8.0) was added to each procaspase-3 sample. All sampleswere then stored at −80° C. until the time-course was completed. Allsamples were then incubated at 95° C. for 5 minutes and run on a 12%SDS-PAGE gel. Proteins were then transferred to nitrocellulose paperovernight. Blots were washed in TTBS (150 mM NaCl, 50 mM Tris, 0.1%Tween-20, pH 7.4) and blocked with a 10% milk solution for 2 hours.Blots were then incubated in a 1:5000 dilution of anti-Penta His AlexaFluor 647 antibody for 2 hours. The blot was then washed with TTBS andscanned on a Typhoon fluorescence scanner (Amersham Biosciences,SunnyVale Calif.).

Safety catch mutations. The DDD procaspase-3 safety catch (SEQ ID NO:1;SEQ ID NO:2; SEQ ID NO:9) was mutated to ADD (SEQ ID NO:3, SEQ ID NO:4,SEQ ID NO:10), DAD (SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:11) and DDA (SEQID NO:7, SEQ ID NO:8, SEQ ID NO:12) using the quickchange strategy withthe following primers,

(SEQ ID NO: 13) gacagacagtggtgttgCGgatgacatggcgtgtcataaaatacc,(SEQ ID NO: 14) gacagacagtggtgttgatgCtgacatggcgtgtcataaaatacc  and(SEQ ID NO: 15) gacagacagtggtgttgatgatgCcatggcgtgtcataaaataccrespectively. See also FIG. 9 and FIG. 10 . Mutated bases are underlinedand capitalized. All mutant plasmids were sequenced to ensure propersequence throughout the gene. All mutant plasmids were expressed exactlyas wild-type procaspase-3 as described above. The ability of PAC-1 toactivate each procaspase-3 mutant was determined by adding variousconcentrations of PAC-1 to 90 μL of a 50 ng/mL wild-type procaspase-3and mutant procaspase-3 in caspase assay buffer in a 96-well plate. Theplate was then incubated for 12 hours at 37° C. 10 μL of a 2 mM solutionof Ac-DEVD-pNA (SEQ ID NO: 28) in caspase assay buffer was then added toeach well. The plate was read every 2 minutes at 405 nm for 2 hours in aSpectra Max Plus 384 well plate reader. The slope of the linear portionfor each well was determined and the fold increase in activity for eachmutant was calculated.

Effect of pH on PAC-1 activation of procaspase-3. The effect of pH onprocaspase-3 activation by PAC-1 was determined by diluting procaspase-3in pH caspase assay buffer (25 mM MES, 25 mM Tris, 25 mM HEPES, 25 mMPIPES, 100 mM NaCl, 10 mM DTT, 0.1 mM EDTA, 0.1% CHAPS and 10% glycerol)to a concentration of 50 ng/mL. The buffer was then changed to variouspH values and 90 μL was added to each well of a 96-well plate. PAC-1 wasadded to a concentration of 100 μM or DMSO was added as a control foreach pH value. The plate was then incubated for 12 hours at 37° C. 10 μLof a 2 mM solution of Ac-DEVD-pNA (SEQ ID NO: 28) in caspase assaybuffer was then added to each well. The plate was read every 2 minutesat 405 nm for 2 hours in a Spectra Max Plus 384 plate reader (MolecularDevices, Sunnyvale Calif.). The slope of the linear portion for eachwell was determined and the fold increase in activation for each pHvalue was calculated.

Annexin V staining. 500 μL of media containing 200 μM PAC-1 or only DMSOas a control was added to the wells of a 24-well plate. 500 μL HL-60cells at a concentration of 2×10⁶ cells/mL were then added to the24-well plate. The plate was incubated for 20 hours at 37° C. Cells wereharvested by centrifugation and washed twice in PBS. The cells were thenwashed in AnnexinV binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mMCaCl2), pH 7.4) and resuspended in 100 μL of Annexin V binding buffer. 5μL of annexin V, Alexa Fluor 488 conjugate was added and the tubes wereincubated at room temperature for 15 minutes protected from light. 400μL of Annexin V binding buffer was then added, followed by the additionof 1 μL of a 1 mg/mL solution of propidium iodide. The fluorescentintensity of each cell was determined by flow cytometry at 525 nm (greenchannel) and 675 nm (red channel). At least 50,000 cells were analyzedin each experiment.

Condensed chromatin staining. 500 μL of media containing 200 μM PAC-1 oronly DMSO as a control was added to the wells of a 24-well plate. 500 μLHL-60 cells at a concentration of 2×10⁶ cells/mL were then added to the24-well plate. The cells were incubated for 20 hours and harvested bycentrifugation. The cells were then washed in PBS buffer followed by theaddition of ice-cold 100% ethanol. The cells were fixed overnight at 4°C. Fixed cells were incubated with 2 μg/mL Hoechst-33258 for 30 minutesat room temperature. A drop of cells was then added to a microscopeslide and covered with a No. 1 thickness coverslip. Condensed chromatinwas observed at 400× magnification on a Zeiss Axiovert 100 microscope.

Cell death inhibition by z-vad-fmk. 100 μL HL-60 cells at aconcentration of 5×10⁵ cells/mL were added to the wells of a 96-wellplate. The cells were then incubated for 1 hour in the presence orabsence of 100 μM z-vad-fmk, a cell-permeable pan caspase inhibitor.PAC-1 was then added at various concentrations, and the cells wereincubated for an additional 24 hours. Cell death was quantitated by theaddition of 20 μL of the MTS/PMS CellTiter 96 Cell Proliferation Assayreagent to each well. The plates were incubated at 37° C. forapproximately 45 minutes until the colored product formed. Theabsorbance was then measured at 490 nm in a Spectra Max Plus 384 platereader (Molecular Devices, Sunnyvale Calif.).

In vivo determination of mitochondrial membrane potential. 1 mL of HL-60cells at a concentration of 1×10⁶ cells/mL were added to the wells of a24-well plate. PAC-1 was then added to a concentration of 100 μM or onlyDMSO was added as a control. The cells were incubated for various times,and the cells then were harvested by centrifugation. The cells werewashed in PBS and resuspended in 1 mL of PBS. 10 μg of the JC-9 dye wasadded and the cells were incubated at room temperature for 10 minutesprotected from light. The cells were then washed two times with PBS andbrought up in 500 μL PBS. The fluorescent intensity of each cell wasdetermined by flow cytometry at 525 nm (green channel) and 675 nm (redchannel). 50,000 cells were analyzed in each experiment. The shift inthe red channel was then used to determine the amount of mitochondrialmembrane depolarization.

In vivo determination of caspase-3 like activity. The amount ofcaspase-3 like protease activity was determined by the amount ofAc-DEVD-pNA (N-acetyl-ASP-Glu-Val-Asp-p-nitroanilide) (SEQ ID NO: 28)cleaved per minute by cell lysates. To accomplish this, 50 μL of mediacontaining varying concentrations of PAC-1 was added to the wells of a96-well plate. 50 μL of HL-60 cells at a concentration of 5×10⁶ cells/mLwere added to the plate and incubated for various times. After theincubation period, the plate was spun at 1000×g for 5 minutes to pelletthe cells. The cells were then washed with 100 μL of PBS and resuspendedin 150 μL of ice-cold Caspase Assay Buffer. Each well was then sonicatedto lyse the cells. 90 μL of cell lysate was transferred from each wellinto a new plate. Ac-DEVD-pNA (SEQ ID NO: 28) was added into each wellto give a final concentration of 200 μM. The plate was then read every 2minutes at 405 nm for 2 hours in a Spectra Max Plus 384 plate reader(Molecular Devices, Sunnyvale Calif.). The slope of the linear portionfor each well was determined and the amount of Ac-DEVD-pNA (SEQ ID NO:28) cleaved per minute was calculated.

In vivo determination of PARP cleavage. The amount of PARP cleavage wasdetermined by using an in vivo PARP activity assay. To accomplish this,50 μL of media containing 200 μM NAD⁺ was added to the control wells ofa 96-well plate. 50 μL of media containing 200 μM PAC-1 and 200 μM NAD⁺was then added to the experimental wells. 25 μL of HL-60 cells at aconcentration of 5×10⁶ cells/mL were then added to each well. The cellswere incubated for various times and then spun at 1000×g for 5 minutes.The cell media was removed and replaced with 50 μL Lysing PARP Buffer(50 mM Tris, 10 mM MgCl2, pH 8.0, 1% Triton X-100) containing 25 mMH₂O₂. The plate was then incubated for 60 minutes at 37° C. To determinethe amount of NAD⁺ still present, 20 μL of 2 M KOH and 20 μL of a 20%(v/v) acetophenone (in ethanol) solution was added to each well of the96-well plate. The plate was then incubated for 10 minutes at 4° C. 90μL of an 88% (v/v) formic acid solution was added to each well of the96-well plate. The plate was then incubated for 5 min. in an oven set to110° C. The plate was allowed to cool and then read on a CriterionAnalyst AD (Molecular Devices, Sunnyvale, Calif.) with an excitation of360 nm, an emission of 445 nm and a 400 nm cutoff dichroic mirror. Thefluorophore was excited using a 1000 W continuous lamp for 1.6×10⁵ μswith 5 reads performed per well. The number of moles of NAD⁺ cleaved perminute was then calculated and the remaining PARP activity as comparedto control wells was determined.

Relative concentration of procaspase-3 in various cell lines. U-937,HL-60 and human bone marrow cells were harvested by centrifugation whileall other cell lines were first trypsinized to release the cells andthen harvested by centrifugation. All cells were washed in PBS andresuspended in 1 mL of ice-cold 100% ethanol. Cells were fixed overnightat 4° C. The cells were spun at 1000×g for 5 minutes, washed with PBSand 100 μL of a 1:100 dilution of anti-caspase-3 antibody in PBS wasthen added. The cells were incubated for 2 hours at room temperaturefollowed by five PBS washes. The cells were then resuspended in 1 mL ofa 1:10,000 dilution of anti-mouse Ab Cy3 labeled antibody for 2 hours atroom temperature protected from light. The cells were washed five timeswith PBS and resuspended in 500 μL of PBS. The fluorescent intensity ofeach cell was determined by flow cytometry at 675 nm (red channel). Atleast 20,000 cells were analyzed in each experiment. The median of thepopulation was used to determine the relative concentration ofprocaspase-3 in each cell line.

Determination of IC₅₀ values in various cell lines. 50 μL of mediacontaining various concentrations of PAC-1 or etoposide was added toeach well of a 96-well plate except control wells, which contained onlyDMSO. U-937, HL-60 and human bone marrow cells were harvested bycentrifugation, while all other cell lines were first trypsinized beforecentrifugation. Cells were then resuspended in media and diluted toeither 1×10⁶ cells/mL for U-937, HL-60 and human bone marrow cells or50,000 cells/mL for all other cell lines. 50 μL of the cell solutionswere then added to each well and the plates were incubated for either 24or 72 hours for etoposide and PAC-1 respectively. Cell death wasquantitated by the addition of 20 μL of the MTS/PMS CellTiter 96 CellProliferation Assay reagent to each well. The plates were then incubatedat 37° C. for approximately one hour until the colored product formed.The absorbance was measured at 490 nm in a Spectra Max Plus 384 platereader (Molecular Devices, Sunnyvale Calif.).

Data Analysis: The data from all flow cytometry experiments was analyzedusing Summit Software (Cytomation, Fort Collins Colo.). All graphs wereanalyzed using Table Curve 2D.

Professor Ronald Hoffman (University of Illinois-Chicago Cancer Center)provided human bone marrow. Professor Guy Salvesen (Burnham Institute)provided the procaspase-3 and procaspase-7 expression vectors.

REFERENCE TO SEQUENCE LISTING—Appendix A. The separately accompanyingsequence listing information, designated Appendix A, is to be consideredand incorporated as part of the specification herewith.

TABLE 1 Overview of Sequence Listing information. SEQ ID NO: BriefDescription Type 1 Procaspase-3; with amino acid DDD wild-type DNA/RNAsafety catch sequence (ACCESSION Number NM_004346) 2 automatictranslation PRT 3 procaspase-3 mutant ADD DNA/RNA 4 automatictranslation PRT 5 procaspase-3 mutant DAD DNA/RNA 6 automatictranslation PRT 7 procaspase-3 mutant DDA DNA/RNA 8 automatictranslation PRT 9 procaspase-3 wild-type DDD PRT 10 procaspase-3 mutantADD PRT 11 procaspase-3 mutant DAD PRT 12 procaspase-3 mutant DDA PRT 13PCR primer1 DNA 14 PCR primer2 DNA 15 PCR primer3 DNA 16 Procaspase-7with amino acid DTD wild-type DNA/RNA safety catch sequence (AccessionNumber NM_001227) 17 automatic translation PRT 18 Procaspase-7 DDDwild-type safety catch DNA/RNA sequence 19 automatic translation PRT 20Procaspase-7 DTD wild-type safety catch, active DNA/RNA site C to Amutant sequence 21 automatic translation PRT 22 Procaspase-7 DDDwild-type safety catch, active DNA/RNA site C to A mutant sequence 23automatic translation PRT 24 Procaspase-7 with amino acid DTD PRT 25Procaspase-7 DDD wild-type safety catch PRT sequence 26 Procaspase-7 DTDwild-type safety catch, active PRT site C to A mutant sequence 27Procaspase-7 DDD wild-type safety catch, active PRT site C to A mutantsequence

Example 2. Synthesis of Procaspase Activating Compounds

PAC-1 and other compounds are prepared according to the followingschemes, e.g., Scheme 1 and/or Scheme 2. Further variations are preparedaccording to methods known in the art.

In a particular example, PAC-1 can be prepared according to Scheme 2:

Example 3. Analogs of PAC-1

Analog compounds of PAC-1 were prepared and assessed for the capabilityto directly activate purified procaspase-3 in vitro.

TABLE 2 Activity of PAC-1 and analog compounds. Compound/ Structuredesignation Structure Activity PAC-1

Active 5

Active 6

Inctive 7

Inactive 2

Inactive 4

Inactive

Example 4. Pharmaceutical Embodiments

The following describes information relevant to pharmaceutical andpharmacological embodiments and is further supplemented by informationin the art available to one of ordinary skill. The exact formulation,route of administration and dosage can be chosen by an individualphysician in view of a patient's condition (see e.g., Fingl et al., inThe Pharmacological Basis of Therapeutics, 1975, Ch. 1, page 1).

It should be noted that the attending physician would know how to andwhen to terminate, interrupt, or adjust administration due to toxicity,or to organ dysfunctions, etc. Conversely, the attending physician wouldalso know to adjust treatment to higher levels if the clinical responsewere not adequate (in light of or precluding toxicity aspects). Themagnitude of an administered dose in the management of the disorder ofinterest can vary with the severity of the condition to be treated andto the route of administration. The severity of the condition may, forexample, be evaluated, in part, by standard prognostic evaluationmethods. Further, the dose and perhaps dose frequency, can also varyaccording to circumstances, e.g. the age, body weight, and response ofthe individual patient. A program comparable to that discussed abovealso may be used in veterinary medicine.

Depending on the specific conditions being treated and the targetingmethod selected, such agents may be formulated and administeredsystemically or locally. Techniques for formulation and administrationmay be found in Alfonso and Gennaro (1995) and elsewhere in the art.Suitable routes may include, for example, oral, rectal, transdermal,vaginal, transmucosal, or intestinal administration; parenteraldelivery, including intramuscular, subcutaneous, or intramedullaryinjections, as well as intraocular, intrathecal, intravenous, orintraperitoneal administration.

For injection or other routes, agents of the invention may be formulatedin aqueous solutions, preferably in physiologically compatible bufferssuch as Hanks' solution, Ringer's solution, water for injection,physiological saline buffer, or other solution. For transmucosaladministration, penetrants appropriate to the barrier to be permeatedcan be used in the formulation. Such penetrants are known in the art.

Use of pharmaceutically acceptable carriers to formulate the compoundsherein disclosed for the practice of the invention into dosages suitablefor systemic or other administration is within the scope of theinvention. With proper choice of carrier and suitable manufacturingpractice, the compositions of the present invention, in particular thoseformulated as solutions, may be administered parenterally, such as byintravenous injection, or other routes. Appropriate compounds can beformulated readily using pharmaceutically acceptable carriers well knownin the art into dosages suitable for oral administration. Such carriersenable the compounds of the invention to be formulated as tablets,pills, capsules, liquids, gels, syrups, slurries, elixirs, solutions,suspensions and the like, e.g. for oral ingestion by a patient to betreated. For other routes, formulations can be prepared for creams,ointments, lotions, and the like.

Agents intended to be administered intracellularly may be administeredusing techniques well known to those of ordinary skill in the art. Forexample, such agents may be encapsulated into liposomes, other membranetranslocation facilitating moieties, or other targeting moieties; thenadministered as described above. Liposomes can include spherical lipidbilayers with aqueous interiors. All molecules present in an aqueoussolution at the time of liposome formation can be incorporated into theaqueous interior. The liposomal contents are both protected from theexternal microenvironment and, because liposomes fuse with cellmembranes, are efficiently delivered into the cell cytoplasm.Additionally, due to hydrophobicity attributes, small organic moleculesmay be directly administered intracellularly.

Pharmaceutical compositions suitable for use in the present inventioninclude compositions wherein the active ingredients are contained in aneffective amount to achieve the intended purpose. Determination of theeffective amounts is well within the capability of those skilled in theart, especially in light of the disclosure provided herein and otherinformation in the art.

In addition to the active ingredients, these pharmaceutical compositionsmay contain suitable pharmaceutically acceptable carriers comprisingexcipients and auxiliaries which facilitate processing of the activecompounds into preparations which can be used pharmaceutically. Thepreparations formulated for oral administration may be in the form oftablets, dragees, capsules, or solutions, including those formulated fordelayed release or only to be released when the pharmaceutical reachesthe small or large intestine.

The pharmaceutical compositions of the present invention may bemanufactured in a manner that is itself known, e.g., by means ofconventional mixing, dissolving, suspending, granulating, dragee-making,levitating, emulsifying, encapsulating, entrapping, lyophilizing, andother processes.

Pharmaceutical formulations for parenteral administration includeaqueous solutions of the active compounds in water-soluble form.Additionally, suspensions of the active compounds may be prepared asappropriate oily injection suspensions. Suitable lipophilic solvents orvehicles include fatty oils such as sesame oil, or synthetic fatty acidesters, such as ethyl oleate or triglycerides, or liposomes. Aqueousinjection suspensions may contain substances which increase theviscosity of the suspension, such as sodium carboxymethyl cellulose,sorbitol, or dextran. Optionally, the suspension may also containsuitable stabilizers or agents which increase the solubility of thecompounds to allow for the preparation of highly concentrated solutions.

Pharmaceutical preparations for oral use can be obtained by combiningthe active compounds with solid excipient, optionally grinding aresulting mixture, and processing the mixture of granules, after addingsuitable auxiliaries, if desired, to obtain tablets or dragee cores.Suitable excipients are, in particular, fillers such as sugars,including lactose, sucrose, mannitol, or sorbitol; cellulosepreparations such as, for example, maize starch, wheat starch, ricestarch, potato starch, gelatin, gum tragacanth, methyl cellulose,hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/orpolyvinylpyrrolidone (PVP). If desired, disintegrating agents may beadded, such as the cross-linked polyvinyl pyrrolidone, agar, or alginicacid or a salt thereof such as sodium alginate.

Dragee cores are optionally provided with suitable coatings. For thispurpose, concentrated sugar solutions may be used, which may optionallycontain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel,polyethylene glycol, and/or titanium dioxide, lacquer solutions, andsuitable organic solvents or solvent mixtures. Dyestuffs or pigments maybe added to the tablets or dragee coatings for identification or tocharacterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fitcapsules made of gelatin, as well as soft, sealed capsules made ofgelatin and a plasticizer, such as glycerol or sorbitol. The push-fitcapsules can contain the active ingredients in admixture with fillersuch as lactose, binders such as starches, and/or lubricants such astalc or magnesium stearate and, optionally, stabilizers. In softcapsules, the active compounds may be dissolved or suspended in suitableliquids, such as fatty oils, liquid paraffin, or liquid polyethyleneglycols. In addition, stabilizers may be added.

Example 5. Direct Induction of Apoptosis in Cancer Cells with a SmallMolecule Activator of Procaspase-3

ABSTRACT. Mutation or aberrant expression of proteins in the apoptoticcascade is a hallmark of cancer. These changes prevent proapoptoticsignals from being transmitted to the executioner caspases, thuspreventing apoptotic cell death and allowing cellular proliferation.Caspase-3 and caspase-7 are the key executioner caspases, existing asinactive zymogens that are activated by upstream signals. Importantly,levels of procaspase-3 are significantly higher in certain cancerouscells relative to non-cancerous controls. Here we report theidentification of a small molecule (PAC-1) that directly activatesprocaspase-3 to active caspase-3 in vitro with an EC₅₀ of 220 nanomolar,and induces apoptosis in a variety of cancer cell lines.

In contrast to many known anti-cancer drugs, cells treated with PAC-1show an immediate activation of procaspase-3, and the efficacy of PAC-1is shown to be proportional to the amount of procaspase-3 contained in acell. Derivatives of PAC-1 that do not activate procaspase-3 in vitroalso have no proapoptotic activity. Cancerous cells isolated fromprimary colon tumors are considerably more sensitive to apoptoticinduction by PAC-1 than the cells from adjacent non-cancerous tissuefrom the same patient; these cancerous cells contain on average about7-fold more procaspase-3 than the cells from the adjacent non-cancerousprimary tissue. In addition, the sensitivity to PAC-1 of the primarycells from the colon cancer tumors strongly correlates with the level ofthe procaspase-3 target. Finally, PAC-1 as a single entity was shown asactive to retard the growth of tumors in three different mouse models,including two models where PAC-1 was administered orally. Thus PAC-1directly activates procaspase-3 to caspase-3 in vivo, thereby allowingthis compound to induce apoptosis even in cells that have defectiveapoptotic machinery. PAC-1 is the first small molecule known to directlyactivate procaspase-3; the direct activation of executioner caspases isan anti-cancer strategy that may prove beneficial in the many cancers inwhich procaspase-3 levels are elevated.

INTRODUCTION. A hallmark of cancer is its resistance to naturalapoptotic signals. Depending on the cancer type, this resistance istypically due to either up- or down-regulation of key proteins in theapoptotic cascade, or to mutations in genes encoding these proteins.Such changes occur in both the intrinsic apoptotic pathway, whichfunnels through the mitochondria and caspase-9, and the extrinsicapoptotic pathway, which involves the action of death receptors andcaspase-8. For example, alterations in proper levels of p53, Bim, Bax,Apaf-1, FLIP and many others have been observed in cancers and lead to adefective apoptotic cascade, one in which the upstream pro-apoptoticsignal is not properly transmitted to activate the executioner caspases,caspase-3 and caspase-7. As most apoptotic pathways ultimately involvethe activation of procaspase-3, these genetic abnormalities areeffectively “breaks” in the apoptotic circuitry, and as a result suchcells proliferate uncontrolled.

Given the central role of apoptosis in cancer, efforts have been made todevelop therapeutics that target specific proteins in the apoptoticcascade. For instance, peptidic or small molecule binders to p53,proteins in the Bcl family, or to the IAPs have pro-apoptotic activity,as do compounds that promote the oligomerization of Apaf-1. However,because many of these compounds target early or intermediate positionson the apoptotic cascade, cancers with mutations in downstream proteinswill likely be resistant to their effects. For therapeutic purposes, itwould be ideal to identify a small molecule that directly activates aproapoptotic protein far downstream in the apoptotic cascade. Inaddition, such a therapeutic strategy would have a higher likelihood ofsuccess if levels of that proapoptotic protein were elevated in cancercells.

The conversion of procaspase-3 to caspase-3 results in the generation ofthe active “executioner” caspase that subsequently catalyzes thehydrolysis of a multitude of protein substrates. Active caspase-3 is ahomodimer of heterodimers and is produced by proteolysis ofprocaspase-3. In vivo, this proteolytic activation typically occursthrough the action of caspase-8 or caspase-9. To ensure that thiszymogen is not prematurely activated, procaspase-3 has a tri-asparticacid “safety catch” that blocks access to the IETD site of proteolysis.This safety catch enables procaspase-3 to resist autocatalyticactivation and proteolysis by caspase-9. The position of the safetycatch is sensitive to pH; thus, upon cellular acidification (as occursduring apoptosis) the safety catch is thought to allow access to thesite of proteolysis, and active caspase-3 can be produced either by theaction of caspase-9 or through an autoactivation mechanism.

Cells from certain types of cancerous tissue have elevated levels ofprocaspase-3. A study of primary isolates from 20 colon cancer patientsrevealed that on average procaspase-3 was elevated six-fold in suchisolates relative to adjacent non-cancerous tissue. In addition,procaspase-3 levels are elevated in certain neuroblastomas, lymphomas,and liver cancers. In fact, a systematic evaluation of procaspase-3levels in the 60 cell-line panel used by the NCI revealed thatparticular lung, melanoma, renal, and breast cancers show greatlyenhanced levels of procaspase-3. Given the central importance of activecaspase-3 to successful apoptosis, the high levels of procaspase-3 incertain cancerous cell types, and the intriguing safety catch-mediatedsuppression of its autoactivation, we reasoned that small molecules thatdirectly activate procaspase-3 could be identified and that suchmolecules could have great potential in targeted cancer therapy. In thisexample, we report the in vitro identification of a small moleculeactivator of procaspase-3, PAC-1. PAC-1 is powerfully proapoptotic incancer cell lines in a manner proportional to procaspase-3 levels, itsproapoptotic effect is due to its direct and immediate activation ofprocaspase-3, and it is effective against primary colon cancer isolatesand in three different mouse models of cancer.

Approximately 20,500 structurally diverse small molecules were screenedfor the ability to activate procaspase-3 in vitro. Procaspase-3 wasexpressed and purified in E. coli according to standard procedures.Procaspase-3 was added to the wells of a 384-well plate, and thecompounds were added to a final concentration of about 40 μM (the finalconcentration of procaspase-3 was 50 ng/mL). Each plate was thenincubated for two hours at 37° C., after which the caspase-3 peptidicsubstrate Ac-Asp-Glu-Val-Asp-p-nitroanilide (Ac-DEVD-pNa) (SEQ ID NO:28) was added to a concentration of 200 μM. The formation of thep-nitroaniline chromophore was followed at 405 nm over the course of twohours. Of the ˜20,500 compounds evaluated, four induced a significantincrease over background in the hydrolysis of the peptidic caspase-3substrate. Of those four, one showed a strong dose dependent effect onin vitro procaspase-3 activation. As shown in FIG. 1A, this firstprocaspase-activating compound (PAC-1) gives half-maximal activation ofprocaspase-3 at a concentration of 0.22 μM. This compound is not simplyincreasing the activity of caspase-3 itself, as it has no effect on thecatalytic activity of the fully processed caspase-3 enzyme (FIG. 1A).

Procaspase-3 consists of a N-terminal pro domain (residues 1-28),followed by a large subunit (17 kDa) and a small subunit (12 kDa) thatare separated by an intersubunit linker.²² In vivo, two procaspase-3monomers assemble to form a homodimer that can be activated by cleavageat D175 in the intersubunit linker. The precise role of the pro domainis unclear, and it has been shown that cleavage in the intersubunitregion alone is sufficient for full catalytic activity. Althoughprocaspase-3 has enough catalytic activity to drive its own proteolyticmaturation, it is highly resistant to this autoactivation due to thepresence of the three-amino acid safety catch. However, when the safetycatch is mutated significant autoactivation of procaspase-3 is observed.To directly assess the ability of PAC-1 to catalyze the maturation ofprocaspase-3 to the active caspase-3, the procaspase-3 protein wasincubated with 100 μM of PAC-1 for time points ranging from one to fivehours. As shown by the Western blot in FIG. 1B, PAC-1 induces thecleavage of procaspase-3 in a time-dependant fashion, with >50%processing observed after 4 hours. In contrast, procaspase-3 incubatedin buffer shows virtually no autoactivation over that same time span.PAC-1 was also effective in this assay at a concentration of 5 μM.

Alanine substitutions were then made in the key aspartic acid triad inthe safety catch region of procaspase-3, residues Asp179, Asp180 andAsp181. Mutations at these positions all dramatically decreased theability of PAC-1 to activate procaspase-3, with certain mutations moredetrimental to activation of procaspase-3 by PAC-1 (FIG. 2A). Likecaspase-3, caspase-7 also exists as an inactive zymogen that isactivated by proteolysis. Caspase-3 and caspase-7 are both executionercaspases and have considerable structural homology. Procaspase-7 is alsopredicted to have a similar safety catch region, although it has onlytwo aspartic acids in the key triad (Asp-Thr-Asp), instead of three. Asindicated by the data in FIG. 2B, PAC-1 can also activate procaspase-7,although in a less efficient manner than its activation of procaspase-3(EC₅₀ of 4.5 μM versus 0.22 μM for procaspase-3 activation). The potencyof procaspase-7 activation by PAC-1 is similar to its effect on theAsp-Ala-Asp mutant of procaspase-3 (EC₅₀=2.77 μM). As expected, theeffect of PAC-1 is abolished at low pH values where procaspase-3undergoes rapid autoactivation (FIG. 2C).

PAC-1 was found to induce apoptosis in a variety of cancer cell lines.In HL-60 cells addition of PAC-1 leads to considerablephosphatidylserine exposure on the cell membrane accompanied bysignificant chromatin condensation (FIGS. 3A, 3B). In addition, thecompound induces cleavage of the caspase substrate PARP-1 (as assessedby an in vivo PARP activity assay) and causes mitochondrial membranedepolarization (see below). Significant cellular blebbing of PAC-1treated cells was also observed by microscopy. Furthermore, the toxicityof PAC-1 could be abolished in the presence of the caspase inhibitorz-VAD-fmk.

If PAC-1 is indeed inducing apoptosis via direct activation ofprocaspase-3, then the time course of apoptotic events should be alteredrelative to that observed with standard proapoptotic agents. Etoposideis well known to induce apoptosis through the intrinsic pathway; thus,mitochondrial membrane depolarization is followed by procaspase-3activation in etoposide-treated cells. Indeed, in HL-60 cells treatedwith 10 μM etoposide, mitochondrial membrane depolarization is observed,followed by detection of caspase-3-like activity (FIG. 4A). In contrast,treatment of cells with PAC-1 gives a markedly different result. Withthis compound, the first observed biochemical hallmark of apoptosis iscaspase-3-like enzymatic activity, with activity noted within minutes ofPAC-1 addition and 50% activation taking place in just over 2 hours andwell before any significant mitochondrial membrane depolarization (FIG.4B). In addition, PARP-1 activity is rapidly reduced in cells treatedwith PAC-1, whereas this reduction is observed at later time points inetoposide treated cells (FIG. 4C); control experiments show that PAC-1does not directly inhibit enzymatic activity of PARP-1. In the typicalsequence of apoptotic events the mitochondrial membrane depolarizes,caspases are activated, and caspase substrates (such as PARP-1) arecleaved. The observation that cells treated with PAC-1 show a rapidactivation of caspase-3/-7 (before mitochondrial membranedepolarization) and a rapid cleavage of a caspase substrate (PARP-1) isindicative of PAC-1 exerting its cellular toxicity through the directactivation of procaspase-3.

To further define the potency of PAC-1, the ability of this compound toinduce cell death in cancer cell lines with varying levels ofprocaspase-3 was assessed. A determination was first made of the levelsof procaspase-3 present in multiple cancer cell lines (leukemia,lymphoma, melanoma, neuroblastoma, breast cancer, lung cancer, adrenalcancer and renal cancer). The IC₅₀ values for cell death induction wereobtained for PAC-1 versus these cell lines. The combined data shows astrong correlation between cellular concentration of procaspase-3 andsensitivity to PAC-1 (FIG. 4D, FIG. 4E). PAC-1 is most potent versus thelung cancer cell line NCI-H226, with an IC₅₀ of 0.35 μM. We found thiscell line to have a concentration of procaspase-3 that is greater thanfive times that of baseline levels. Importantly, there is one cancercell line (MCF-7, breast cancer cells) that is known to have noexpression of procaspase-3. PAC-1 has virtually no effect on MCF-7cells, inducing death with an IC₅₀>75 μM.

In contrast, etoposide showed no such correlation between potency incell culture and cellular levels of procaspase-3. For instance,etoposide was ineffective (IC₅₀>50 μM) in inducing death in three of themelanoma cell lines (UACC-62, CRL-1872, and B16-F10), the breast cancercell line (Hs 578t), and the lung cancer cell line (NCI-H226); thesecell lines have procaspase-3 levels of 1.0, 2.4, 1.9, 3.7, and 5.3,respectively. Etoposide was effective (IC₅₀<1 μM) versus HL-60, U-937,SK-N-SH and PC-12, which have procaspase-3 levels of 4.3, 4.0, 4.7, and4.4, respectively. Thus, overall there is no correlation betweenprocaspase-3 levels and IC₅₀ for etoposide.

Several derivatives of PAC-1 were synthesized and evaluated for boththeir procaspase-3 activating properties and their effects on cancercells in cell culture (Table 3). The PAC-1 derivative that lacks theallyl group (de-allyl PAC-1) is able to induce procaspase-3 activationand cell death at levels similar to PAC-1. However, all otherderivatives showed no activity in either assay. Thus, while it appearsthe allyl group is dispensable for biological activity, the phenolichydroxyl and aromatic rings are all critical for PAC-1 activity. Thisdata is also consistent with the proposed mechanism of action of PAC-1;compounds that do not activate procaspase-3 in vitro have noproapoptotic effect on cancer cells in culture.

To test this direct, small molecule-mediated procaspase-3 activationstrategy in clinical isolates of cancer, we obtained freshly resectedcolon tumors (together with adjacent non-cancerous tissue) from 18patients from Carle Foundation Hospital (Urbana, Ill.). The cancerousand non-cancerous tissue was separated, and the cells derived from thesewere evaluated for their levels of procaspase-3 and their sensitivity toPAC-1. As shown in FIG. 5A, in all cases the cancerous cells hadelevated levels (1.7- to 17.2-fold, with an average of 7.6-foldelevation) of procaspase-3 relative to the cells from the adjacentnon-cancerous tissue from the same patient. Further, these cancerouscells were quite susceptible to death induction by PAC-1. PAC-1 inducedcell death in the primary cancerous cells with IC₅₀ values from0.007-1.41 μM, while PAC-1 induced cell death in the adjacentnon-cancerous tissue with IC₅₀ values from 5.02-9.98 μM (FIG. 5B andTable 4). The cancerous tissue that had elevated levels of procaspase-3was extremely sensitive to PAC-1. For example, PAC-1 induced death inthe cancer cells from patient 17 with an IC₅₀ of 7 nM, and these cellswere over 700-fold more sensitive to PAC-1 than cells from the adjacentnormal tissue. See also FIG. 6A showing relative procaspase-3concentrations in normal and cancerous samples from Patients 1, 2, and 3over a period of time of about 54 days; FIG. 6B illustrates that cellsin cancerous tissue can be greater than about 80-fold more sensitive toPAC-1 in comparison with normal tissue.

In addition to cells from the non-cancerous tissue of the 18 patients,PAC-1 was also evaluated against four other non-cancerous cell types:white blood cells isolated from the bone marrow of a healthy donor,Hs888Lu (lung fibroblast cells), MCF-10A (breast fibroblast cells), andHs578Bst (breast epithelial cells). Notably, the non-cancerous celltypes are among those with the lowest amount of procaspase-3, and PAC-1is comparatively less able to induce death in these cells, with IC₅₀values of 3.2-8.5 μM (FIG. 5B, green diamonds). As is apparent from FIG.5B, PAC-1 induces death in a wide variety of cell types (non-cancerouscell lines, non-cancerous primary cells, cancerous cell lines, primarycancerous cells) in a manner directly related to the level ofprocaspase-3. The elevation of procaspase-3 in cancerous cells allowsPAC-1 to selectively induce death in these cell types.

PAC-1 was evaluated in a mouse xenograft model using a slow release modeof drug delivery. In this model, subcutaneous tumors were formed inovariectomized female athymic BALB/c (nude) mice using the ACHN (renalcancer) cell line. Once the tumors were measured to be greater thanabout 30 mm², drug was administered via the implantation of a pellet ofPAC-1 and cholesterol, providing for slow and steady levels of compoundrelease. Three groups of mice were used, with pellets containing 0 mg, 1mg, and 5 mg of PAC-1, six mice per group, with four tumors per mouse.Tumor sizes were monitored for about 8 weeks. As shown in FIG. 5C, tumorgrowth is significantly retarded in the mice that were implanted withthe pellet containing 5 mg of PAC-1. Food intake evaluation in the lastweek of the experiment showed no difference in food consumption betweenthe three groups of mice. After the mice were sacrificed, plasma sampleswere taken from each mouse, and the PAC-1 content of each was analyzed.For mice that received a 5 mg pellet of PAC-1, this analysis revealedPAC-1 to be present at a concentration of 5 nM in the plasma after the54-day experiment.

PAC-1 was evaluated in a second mouse xenograft model, this one usingoral administration as the drug delivery mode. In this model,subcutaneous xenograft tumors were formed in male athymic BALB/c-nu/numice (5 weeks old, SLC, Hamamaysu, Japan) using the NCI-H226 (lungcancer) cell line, eight mice per group, three tumors per mouse. Afterformation of the tumors in the mice, the mice were treated with PAC-1via oral gavage once a day for 21 days at a concentration of 0, 50, or100 mg/kg and sacrificed 1 week later. As clearly indicated by the graphin FIG. 5D, oral administration of PAC-1 significantly retards tumorgrowth in a dose-dependent manner.

Finally, PAC-1 was evaluated in a mouse model where the NCI-H226 cellswere injected into male athymic BALB/c-nu/nu mice via tail veininjection. The total experiment lasted 28 days; the mice were treatedonce a day with PAC-1 (100 mg/kg) via oral gavage on days 1-4 and 7-11.On other days the mice did not receive PAC-1. A second group of micereceived only vehicle. After 28 days the mice were sacrificed, and theirlungs were examined. As shown in FIG. 5E, there is a clear differencebetween the lung of the control mouse (with obvious gray tumor mass) andthe lung of the PAC-1 treated mouse. Results are also shown in a panelfrom an animal treated with gefitinib (Iressa™; AstraZeneca).

Cancerous cells typically have a reduced sensitivity to proapoptoticsignals due to the mutation or aberrant expression of an assortment ofproteins in the apoptotic cascade. As such, many types of cancer arenotoriously resistant to not only the endogenous signals for apoptoticcell death, but also to chemotherapeutic agents that act through similarmechanisms. The paradoxical elevation of procaspase-3 levels in certaincancers provides an opportunity to use this existing intracellular poolof protein to directly induce apoptosis, thus bypassing the oftennon-functional upstream portion of the cascade. PAC-1 induces theautoactivation of procaspase-3 in vitro. In cell culture, PAC-1treatment induces rapid caspase-3-like activity. It is likely that thecaspase-3 mediated cleavage of anti-apoptotic proteins (Bcl-2, Bcl-XL,etc.) then induces depolarization of the mitochondrial membrane andamplifies apoptosis. Further, the potency of PAC-1 toward a variety ofcancerous and non-cancerous cell types is proportional to theconcentration of procaspase-3 in the cell. As the primary cancerouscells isolated from resected colon tumors have elevated levels ofprocaspase-3, these cells are considerably more sensitive to PAC-1 thancells from adjacent non-cancerous tissue. It is worth noting thatseveral of the cell lines against which PAC-1 is effective have faultyapoptotic pathways that make them resistant to apoptosis; for instance,Apaf-1 expression is dramatically decreased in SK-MEL-5 cells, and Bcl-2is overexpressed in the NCI-H226 lung cancer cell line. Finally, PAC-1is effective in three different mouse models of cancer, including twowhere PAC-1 is administered orally.

Data presented herein support the notion that procaspase-3 activatingcompounds can be exceedingly effective against a variety of commoncancers in which procaspase-3 levels are aberrantly high. Assessment ofprocaspase-3 levels in cancer biopsies is simple and rapid; as such, thepotential effectiveness of a compound such as PAC-1 can be assessed apriori with a high degree of accuracy. Such personalized medicinestrategies can be preferential to therapies that rely on generalcytotoxins and can be valuable in anti-cancer therapy. Professor GuySalvesen (Burnham Institute) provided the procaspase-3 and procaspase-7expression vectors.

FIGURE LEGENDS

FIGS. 1 and 2 . The structure of PAC-1 is shown elsewhere in thespecification. FIG. 1A) In vitro activation of procaspase-3 and activecaspase-3 by PAC-1. PAC-1 activates procaspase-3 with an EC₅₀=0.22 μM.FIG. 1B) Cleavage of procaspase-3 to active caspase-3 as induced byPAC-1. Procaspase-3 was recombinantly expressed in E. coli with anN-terminal His-6 tag (SEQ ID NO: 29) and purified. Immunoblotting wasperformed with an anti-His-6 antibody (“His-6” disclosed as SEQ ID NO:29). In the absence of PAC-1 no maturation of procaspase-3 is observed.In the presence of 100 μM PAC-1, cleavage to generate the p19 fragmentis observed within 1 h, and >50% cleavage is observed after 4 h. PAC-1is also effective at 5 μM in this assay. FIG. 2A) Activation of mutantsin the “safety catch” region of procaspase-3 by PAC-1. PAC-1 has an EC₅₀for activation of 0.22 μM on wild type procaspase-3 (DDD), andcorresponding EC₅₀ values of 2.77 μM (DAD), 113 μM (DDA), and 131 μM(ADD) for the mutants. FIG. 2B) PAC-1 activates procaspase-7 with anEC₅₀ of 4.5 μM. FIG. 2C) Dependence of PAC-1 activation of procaspase-3on pH. At low pH the safety catch is off and procaspase-3 is essentiallymaximally activated. Error bars represent standard deviations from themean.

FIGS. 3 and 4 . PAC-1 induces apoptosis in HL-60 cells. FIG. 3A)Phosphatidylserine exposure (as measured by Annexin-V staining) after a20 h treatment with 100 μM PAC-1. PAC-1 is also effective at 5 μM inthis assay (see Supporting FIG. 2 ). FIG. 3B) Chromatin condensation asvisualized by Hoescht staining after a 20 h treatment with 100 μM PAC-1.FIG. 4A) Mitochondrial membrane depolarization (MMP) and caspase-3 likeactivity in HL-60 cells treated with 10 μM etoposide. FIG. 4B)Mitochondrial membrane depolarization (MMP) and caspase-3 like activityin HL-60 cells treated with 100 μM PAC-1. FIG. 4C) PAC-1 treatment (100μM) induces a rapid decrease in cellular PARP activity in HL-60 cells,consistent with an immediate activation of cellular caspase-3/-7. Incontrast, etoposide (10 μM) treated cells show a decrease in PARPactivity at much later time points. FIG. 4D and FIG. 4E) PAC-1 inducescell death in a procaspase-3 dependant manner. For a number of diversecancerous cell lines, the procaspase-3 levels were determined (by flowcytometry with an antibody to procaspase-3) and the IC₅₀ of PAC-1 wasmeasured (through a 72 h treatment with a range of PAC-1 concentrationsand quantitation using the MTS assay). PAC-1 is quite potent (IC₅₀=0.35μM) in the NCI-H226 lung cancer cell line known to have high levels ofprocaspase-3. Error bars represent standard deviations from the mean.

Table 3. PAC-1 and de-allyl PAC-1 activate procaspase-3 in vitro andinduce death in cancer cells in cell culture, but other structuralanalogues have no procaspase-3 activating effect in vitro and give noinduction of death in cell culture.

FIG. 5 . FIG. 5A) Procaspase-3 levels are elevated in cells derived fromfreshly resected colon cancer tissue. Freshly resected primary colontumors (together with adjacent non-cancerous tissue) were obtained from18 different patients, the cancerous and non-cancerous tissue wereseparated, and the procaspase-3 levels were measured for each using anantibody to procaspase-3 and flow cytometry. On average, cells from thecancerous tissue have a 7.6-fold elevation in procaspase-3 as comparedto the cells derived from the adjacent non-cancerous tissue from thesame patient. FIG. 5B) PAC-1 induces cell death in a manner proportionalto the cellular level of procaspase-3. The red circles represent theprimary cancerous cells from the 18 colon tumors. The black trianglesrepresent the same cancer cell lines depicted in FIG. 4D. The greendiamonds are four non-cancerous cell types: Hs888Lu (lung fibroblastcells), MCF-10A (breast fibroblast cells), Hs578Bst (breast epithelialcells), and white blood cells isolated from the bone marrow of a healthydonor. The blue squares are the primary non-cancerous cells isolatedfrom the tumor margins of the 18 patients.

TABLE 3 Selected compounds indicating activity levels. EC₅₀ (μM) forIC₅₀ (μM) for procaspase-3 death induction Compound activation in HL-60cells

0.22 0.92

0.43 1.74

>50 >100

>50 >100

>50 >100

>50 >100

>50 >100

>50 >100

>50 >100

>50 >100

Table 4. Cells derived from primary colon cancer tissue are considerablymore sensitive to death induction by PAC-1 than are cells derived fromadjacent non-cancerous tissue from the same patient.

TABLE 4 Concentration levels of PAC-1 activity in patients. PAC-1, IC₅₀μM Patient Normal Cancerous 1 6.78 0.212 2 9.79 0.154 3 6.61 0.080 49.50 0.340 5 6.88 0.216 6 6.28 0.020 7 7.34 0.422 8 5.67 0.045 9 6.540.844 10 9.98 0.017 11 5.94 1.030 12 5.63 0.052 13 5.50 0.499 14 7.580.366 15 5.96 0.106 16 5.02 0.527 17 5.17 0.007 18 6.39 1.410FIG. 5C) PAC-1 reduces the growth of tumors in a xenograft model ofcancer. Tumors were formed with the ACHN (renal cancer) cell line bysubcutaneous injection, with six mice in each group, and four tumors permouse. Once the tumors grew to about 30 mm² PAC-1 was implanted as acholesterol pellet. Error bars represent standard error from the mean.FIG. 5D) Oral administration of PAC-1 significantly retards tumor growthin a mouse xenograft model. Tumors were formed using the NCI-H226 (lungcancer) cell line by subcutaneous injection, eight mice in each group,and three tumors per mouse. PAC-1 or vehicle was administered once a dayby oral gavage on days 1-21. Error bars represent standard error fromthe mean. FIG. 5E) Oral administration of PAC-1 significantly retardstumor growth in an i.v. injection model. Mice were injected i.v. withthe NCI-H226 (lung cancer) cell line. The mice were treated with PAC-1(100 mg/kg) via oral gavage following the protocol as described in thetext. Images show the lungs of the mice that did not receive PAC-1 andhave a large amount of gray tumor mass on the lung. In contrast, themice that did receive PAC-1 have almost no visible gray matter.

Example 6. Testing of PAC-1 in Mouse Model of Lung Cancer

A xenograft model was employed using NCI-H226 (lung cancer) cells. PAC-1was given intraperitoneally (i.p.) at 10 mg/kg. A comparison of efficacywas performed with gefitinib (Iressa™; AstraZeneca, Wilmington, Del.) at40 mg/kg using 5 mice per group. Results are shown in FIG. 7 ,indicating that PAC-1 was associated with reducing growth in tumorvolume.

Example 7. Combinatorial Derivatives, Synthesis, and Therapeutic Use

A number of compounds are prepared as derivatives of the PAC-1structure. A hydrazide group is reacted with an aldehyde group to yielda combinatorial library of derivative compounds.

Any one of hydrazide precursor groups (AX) designated L1-L20 are used togenerate hydrazides which are reacted with any one of aldehyde groups(BX) designated 1-28, thus yielding 560 PAC-1 derivative compounds. Aderivative compound is synthesized using methods as described herein andaccording to knowledge available in the art. See the scheme andcomponent structures below in addition to FIGS. 8A and 8B.

In an embodiment, such derivative compounds are further modified, e.g.to alter a property such as activity, solubility, toxicity, stability,and/or other properties in connection with pharmaceutical applications.

The derivative compounds are used as anti-cancer agents. Compounds arevalidated as capable of having antineoplastic activity, apoptosisregulation, and/or procaspase-3 activation. For example, primaryisolates of freshly removed colon cancer are used to assess procaspase-3levels and sensitivity of cells to test compound levels, where a testcompound is PAC-1 or a derivative compound. Compounds are classifiedregarding a propensity to induce cell death in cancerous cells versusnormal cells.

In further assessing a derivative compound, in vitro and in vivo testingis performed. Stability in connection with exposure to liver microsomesis evaluated.

Example 8. Activity of Certain Derivatives Relative to PAC-1

PAC-1 and certain derivatives were tested in the HL-60 cell line andIC50 values were determined. The results are indicated in Table 5 (whereL- and R-designations refer to structures shown in the AX and BX seriesabove, respectively). Several of the PAC-1 derivatives exhibited anactivity level that was generally about one order of magnitude greaterthan that of the PAC-1 compound.

TABLE 5 Fold better NAME STRUCTURE IC₅₀ vs. HL-60 than PAC-1 PAC-1L01R03

54.6 uM  1.0 L01R06

 5.63 uM  9.7-fold L02R03

 4.34 uM 12.6-fold L02R06

 6.53 uM  8.4-fold L08R06

 5.31 uM 10.3-fold L09R03

 4.82 uM 11.3-fold L09R06

 4.17 uM 13.1-fold L09R08

 2.42 uM 22.6-fold

Example 9. Further Compounds and Methods

Additional compounds were synthesized and tested for activity. Thesecompounds are designated DX1-17 herein. Structures for these compoundsare shown in FIG. 11 . It is noted that compound DX1 is PAC-1 and thatcompound DX3 is de-allyl PAC-1.

Compounds DX1-DX17 were tested using the HL-60 cell line for the abilityto effect apoptosis, and IC₅₀ values were determined. Activity levels ofcompounds from assays of 72 hrs duration with HL-60 cells are shown inTable 6 and along with structures in FIG. 12 .

TABLE 6 Results for compounds DX1-17 in HL-60 cells. Compound IC₅₀value, (DX) micromolar 1 2.8 2 >80 3 8.7 4 >80 5 >80 6 0.9 7 9.3 8 10.59 1.2 10 20.6 11 3.2 12 4.9 13 47.3 14 >80 15 1.9 16 >100 17 >100

Certain compounds were also tested for the ability to effect in vitroactivation of procaspase-3. Results of Western blots are shown in FIG.13 . FIG. 13A indicates substantial activity levels for compounds PAC-1(alias DX1), DX3, and DX11 relative to the control levels (for lanesindicated with letter “C”). FIG. 13B also illustrates results of testingfor activity of compounds DX1, DX12, DX13, DX15, and DX17; the arrowindicates the location of procaspase-3. Experimental conditions includedcompound concentrations of 50 micromolar, procaspase-3 levels of about35 nanomolar, and treatment periods of 8 hr.

In an embodiment, a DX compound herein is capable of inducing orselectively inducing apoptosis in a cancer cell. In an embodiment, acompound is used as an anti-cancer drug. In an embodiment, a compound isused as a pro-apoptotic agent. In an embodiment, a preferred DX compoundis DX6, DX7, DX8, DX9, DX10, DX11, DX12, or DX15.

Example 10. Synthetic Schemes for Certain Compounds and Methods

Schemes for synthesis of compounds including DX1-DX17 are shown herein.

Example 11. Synthetic Schemes for Certain Compounds and Methods

Schemes for synthesis of further compounds including FX1-FX9 and GX1 areshown herein below.

Example 12. Activity of Certain Compounds

Certain compounds were tested for activity. Results are indicated inFIG. 15 and FIG. 16 . FIG. 15 illustrates results from activity testingof compounds including such in the series DX, FX, and GX. Testconditions used 2.5 μM procaspase-3 (D₃A) with the indicated testcompound at 100 μM (filled columns); and further with 10 μM zinc (opencolumns). FIG. 16 illustrates results from activity testing of compoundsin the series DX and FX, plotted as percent activity versus compoundconcentration.

Assay description—Materials and methods. Compounds were tested in an invitro activity assay. In this assay, an “uncleavable” orcleavage-resistant form of procaspase-3 was used. In this protein, thecleavage sites have been mutated from aspartic acid residues to alanineresidues (D3A). This form of procaspase-3 generally cannot be cleavedthrough autoactivation or by another protease. As such, the activity ofthe compounds on the zymogen can be monitored independent of proteolyticprocessing. In these experiments, 2.5 μM Procaspase-3 (D3A) wasincubated for 1 hour in the presence and absence of 10 μM zinc and thepresence and absence of compounds. The ability of the compounds toactivate procaspase-3 (D3A) was monitored by the use of 100 μMAc-DEVD-pNA (SEQ ID NO: 28) substrate, and the absorbance was monitoredat 405 nm. An amount of 10 μM zinc is sufficient to fully inhibit 2.5 μMProcaspase-3 (D3A). This experiment revealed four classes of compounds:Activators, Inhibitors, Dual mode, and Non-effectors. Compounds thatwere capable of relieving the inhibitory effect of zinc are consideredactivators. Compounds that inhibit procaspase-3 (D3A) activity even inthe absence of zinc are considered inhibitors. Some compounds exhibitthe characteristics of both an activator and an inhibitor, and somecompounds had no effect in this assay.

Compounds that were activators or had dual activity were further testedin a dose response experiment. In this experiment, 2.5 μM Procaspase-3(D3A) was incubated with 10 μM zinc and various concentrations of eachcompound. After incubation for 1 hour, 200 μM Ac-DEVD-pNA (SEQ ID NO:28) was added to each sample and the absorbance was monitored at 405 nm.In this experiment we find that the compounds are able to activateprocaspase-3 in the presence of zinc to varying degrees. Additionally,some of these compounds show inhibition at higher concentrations.

STATEMENTS REGARDING INCORPORATION BY REFERENCE AND VARIATIONS

All references throughout this application, for example patent documentsincluding issued or granted patents or equivalents; patent applicationpublications; unpublished patent applications; and non-patent literaturedocuments or other source material; are hereby incorporated by referenceherein in their entireties, as though individually incorporated byreference, to the extent each reference is at least partially notinconsistent with the disclosure in this application (for example, areference that is partially inconsistent is incorporated by referenceexcept for the partially inconsistent portion of the reference).

Any appendix or appendices hereto are incorporated by reference as partof the specification and/or drawings.

Where the terms “comprise”, “comprises”, “comprised”, or “comprising”are used herein, they are to be interpreted as specifying the presenceof the stated features, integers, steps, or components referred to, butnot to preclude the presence or addition of one or more other feature,integer, step, component, or group thereof. Separate embodiments of theinvention are also intended to be encompassed wherein the terms“comprising” or “comprise(s)” or “comprised” are optionally replacedwith the terms, analogous in grammar, e.g.; “consisting/consist(s)” or“consisting essentially of/consist(s) essentially of” to therebydescribe further embodiments that are not necessarily coextensive. Forclarification, as used herein “comprising” is synonymous with “having,”“including,” “containing,” or “characterized by,” and is inclusive oropen-ended and does not exclude additional, unrecited elements or methodsteps. As used herein, “consisting of” excludes any element, step,component, or ingredient not specified in the claim element. As usedherein, “consisting essentially of” does not exclude materials or stepsthat do not materially affect the basic and novel characteristics of theclaim (e.g., not affecting an active ingredient). In each instanceherein any of the terms “comprising”, “consisting essentially of” and“consisting of” may be replaced with either of the other two terms. Theinvention illustratively described herein suitably may be practiced inthe absence of any element or elements, limitation or limitations whichis not specifically disclosed herein.

The invention has been described with reference to various specific andpreferred embodiments and techniques. However, it should be understoodthat many variations and modifications may be made while remainingwithin the spirit and scope of the invention. It will be appreciated byone of ordinary skill in the art that compositions, methods, devices,device elements, materials, optional features, procedures and techniquesother than those specifically described herein can be applied to thepractice of the invention as broadly disclosed herein without resort toundue experimentation. All art-known functional equivalents ofcompositions, methods, devices, device elements, materials, proceduresand techniques described herein; and portions thereof; are intended tobe encompassed by this invention. Whenever a range is disclosed, allsubranges and individual values are intended to be encompassed. Thisinvention is not to be limited by the embodiments disclosed, includingany shown in the drawings or exemplified in the specification, which aregiven by way of example or illustration and not of limitation. The scopeof the invention shall be limited only by the claims.

CITATIONS

These applications are particularly incorporated by reference inentirety: U.S. Provisional Patent Application No. 60/516,556 byHergenrother et al., filed Oct. 30, 2003; U.S. Provisional PatentApplication No. 60/603,246 by Hergenrother et al., filed Aug. 20, 2004;U.S. application Ser. No. 10/976,186 by Hergenrother et al., filed Oct.27, 2004.

-   U.S. Provisional Application No. 60/684,807 filed May 26, 2005; U.S.    Provisional Application No. 60/743,878 filed Mar. 28, 2006; U.S.    patent application Ser. No. 11/420,425 filed May 25, 2006; PCT    International Application No. PCT/US Ser. No. 06/020,910 filed May    26, 2006; U.S. Provisional Application No. 60/914,592 filed Apr. 27,    2007.-   U.S. Pat. No. 6,762,045, Membrane derived caspase-3, compositions    comprising the same and methods of use therefore; U.S. Pat. No.    6,534,267, Polynucleotides encoding activators of caspases; U.S.    Pat. No. 6,403,765, Truncated Apaf-1 and methods of use thereof;    U.S. Pat. Nos. 6,303,329; 6,878,743 by Choong, et al. issued Apr.    12, 2005; U.S. 2004/0077542 by Wang, Xiaodong; et al., published    Apr. 22, 2004; U.S. 2004/0180828 by Shi, Yigong, published Sep. 16,    2004.-   Slee E A et al., Benzyloxycarbonyl-Val-Ala-Asp (OMe)    fluoromethylketone (Z-VAD.FMK) inhibits apoptosis by blocking the    processing of CPP32, Biochem J. 1996 Apr. 1; 315 (Pt 1):21-4.-   1. Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100,    57-70 (2000).-   2. Okada, H. & Mak, T. W. Pathways of apoptotic and non-apoptotic    death in tumour cells. Nature Rev. Cancer 4, 592-603 (2004).-   3. Roy, S. et al. Maintenance of caspase-3 proenzyme dormancy by an    intrinsic “safety catch” regulatory tripeptide. Proc. Natl. Acad.    Sci. 98, 6132-6137 (2001).-   4. Svingen, P. A. et al. Components of the cell death machine and    drug sensitivity of the National Cancer Institute Cell Line Panel.    Clin. Cancer Res. 10, 6807-6820 (2004).-   5. Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumor suppression.    Nature 432, 307-315 (2004).-   6. Vogelstein, B. & Kinzler, K. W. Achilles' heel of cancer. Nature    412, 865-866 (2001).-   7. Traven, A., Huang, D. C. & Lithgow, T. Protein hijacking: key    proteins held captive against their will. Cancer Cell 5, 107-108    (2004).-   8. Soengas, M. S. et al. Inactivation of the apoptosis effector    Apaf-1 in malignant melanoma. Nature 409, 207-211 (2001).-   9. Wajant, H. Targeting the FLICE inhibitory protein (FLIP) in    cancer therapy. Mol. Interv. 3, 124-127 (2003).-   10. Denicourt, C. & Dowdy, S. F. Targeting apoptotic pathways in    cancer cells.

Science 305, 1411-1413 (2004).

-   11. Vassilev, L. T. et al. In vivo activation of the p53 pathway by    small-molecule antagonists of MDM2. Science 303, 844-848 (2004).-   12. Degterev, A. et al. Identification of small-molecule inhibitors    of interaction between the BH3 domain and Bcl-XL. Nature Cell Biol.    3, 173-182 (2001).-   13. Becattini, B. et al. Rational design and real time, in-cell    detection of the proapoptotic activity of a novel compound targeting    Bcl-XL. Chem. Biol. 11, 389-395 (2004).-   14. Wang, J.-L. et al. Structure-based discovery of an organic    compound that binds Bcl-2 protein and induces apoptosis of tumor    cells. Proc. Natl. Acad. Sci. 97, 7124-7129 (2000).-   15. Li, L. et al. A small molecule Smac mimic potentiates TRAIL- and    TNFa-mediated cell death. Science 305, 1471-1474 (2004).-   16. Nguyen, J. T. & Wells, J. A. Direct activation of the apoptosis    machinery as a mechanism to target cancer cells. Proc. Natl. Acad.    Sci. U.S.A. 100, 7533-7538 (2003).-   17. Jiang, X. et al. Distincitive roles of PHAP proteins and    prothymosin-α in a death regulatory pathway. Science 299, 223-226    (2003).-   18. Boatright, K. M. & Salvesen, G. S. Mechanisms of caspase    activation. Curr. Opin. Cell. Biol. 15, 725-731 (2003).-   19. Nakagawara, A. et al. High levels of expression and nuclear    localization of interleukin-1 β converting enzyme (ICE) and CPP32 in    favorable human neuroblastomas. Cancer Res. 57, 4578-4584 (1997).-   20. Izban, K. F. et al. Characterization of the    interleukin-1β-converting enzyme/Ced-3-family protease,    caspase-3/CPP32, in Hodgkin's disease. Am. J. Pathol. 154, 1439-1447    (1999).-   21. Persad, R. et al. Overexpression of caspase-3 in hepatocellular    carcinomas. Modern Patholo. 17, 861-867 (2004).-   22. Pop, C., Feeney, B., Tripathy, A. & Clark, A. C. Mutations in    the procaspase-3 dimer interface affect the activity of the zymogen.    Biochemistry 42, 12311-12320 (2003).-   23. Stennicke, H. R. et al. J. Biol. Chem. 273, 27084-27090 (1998).-   24. Denault, J.-B. & Salvesen, G. S. Human caspase-7 activity and    regulation by its N-terminal peptide. J. Biol. Chem. 278,    34042-24050 (2003).-   25. Putt, K. S., Beilman, G. J. & Hergenrother, P. J. Direct    quantitation of Poly(ADP-ribose) polymerase (PARP) activity as a    means to distinguish necrotic and apoptotic death in cell and tissue    samples. ChemBioChem 6, 53-55 (2005).-   26. Liang, Y., Nylander, K. D., Yan, C. & Schor, N. F. Role of    caspase 3-dependent Bcl-2 cleavage in potentiation of apoptosis by    Bcl-2. Mol. Pharmacol. 61, 142-149 (2002).-   27. Fujita, N., Nagahshi, A., Nagashima, K., Rokudai, S. &    Tsuruo, T. Acceleration of apoptotic cell death after the cleavage    of Bcl-XL protein by caspase-3-like proteases. Oncogene 17,    1295-1304 (1998).-   28. Earnshaw, W. C., Martins, L. M. & Kaufmann, S. H. Mammalian    caspases: structure, activation, substrates, and functions during    apoptosis. Annu. Rev. Biochem. 68, 383-424 (1999).-   29. Koty, P. P., Zhang, H. & Levitt, M. L. Antisense bcl-2 treatment    increases programmed cell death in non-small cell lung cancer cell    lines. Lung Cancer 23, 115-127 (1999).-   National Center for Biotechnology Information (NCBI) Database of the    National Library of Medicine/National Institutes of Health (NIH)    website: http://www.ncbi.nlm.nih.gov/ using the Gene database to    search for CASP3 (caspase 3, apoptosis-related cysteine protease    [Homo sapiens] GeneID: 836 Locus tag: HGNC: 1504; MIM: 600636,    updated 15 May 2005. Other Aliases: HGNC: 1504, APOPAIN, CPP32,    CPP32B, SCA-1; Other Designations: Human procaspase3 coding    sequence; PARP cleavage protease; SREBP cleavage activity 1; Yama;    caspase 3; cysteine protease CPP32).-   Hergenrother P J. Obtaining and screening compound collections: a    user's guide and a call to chemists. Curr Opin Chem Biol. 2006.-   Silverman S K, Hergenrother P J. Combinatorial chemistry and    molecular diversity Tools for molecular diversification and their    applications in chemical biology. Curr Opin Chem Biol. 2006.-   Goode D R, Sharma A K, Hergenrother P J. Using peptidic inhibitors    to systematically probe the S1′ site of caspase-3 and caspase-7. Org    Lett. 2005 Aug. 4; 7(16):3529-32. PMID: 16048334.-   Dothager R S, Putt K S, Allen B J, Leslie B J, Nesterenko V,    Hergenrother P J. Synthesis and identification of small molecules    that potently induce apoptosis in melanoma cells through G1 cell    cycle arrest. J Am Chem Soc. 2005 Jun. 22; 127(24):8686-96. PMID:    15954774.-   Putt K S, Hergenrother P J. A nonradiometric, high-throughput assay    for poly(ADP-ribose) glycohydrolase (PARG): application to inhibitor    identification and evaluation. Anal Biochem. 2004 Oct. 15;    333(2):256-64. PMID: 15450800.-   Putt K S, Hergenrother P J. An enzymatic assay for poly(ADP-ribose)    polymerase-1 (PARP-1) via the chemical quantitation of NAD(+):    application to the high-throughput screening of small molecules as    potential inhibitors. Anal Biochem. 2004 Mar. 1; 326(1):78-86. PMID:    14769338.-   Nesterenko V, Putt K S, Hergenrother P J. Identification from a    combinatorial library of a small molecule that selectively induces    apoptosis in cancer cells. J Am Chem Soc. 2003 Dec. 3;    125(48):14672-3. PMID: 14640619.-   Putt, Karsone et al., Small scale activation of procaspase-3 as a    personalized anticancer strategy, Nature Chemical Biology    2(10):543-550, S543/1-S543/29 (2006).

What is claimed is:
 1. A pharmaceutical composition comprising a meansfor enhancing the activation of procaspase-3 in a cancer cell, and apharmaceutically acceptable carrier, wherein the means for enhancing theactivation of procaspase-3 in a cancer cell is a compound of Formula ZZ:

wherein two of R_(a), R_(b), R_(c), R_(d) and R_(e) are (C₁-C₃)alkyl,(C₁-C₃)alkoxy or halogen and the remaining groups are hydrogen; each Ris independently hydrogen, halogen, alkoxy, alkenyl, or alkyl, whereinat least one R is a substituent other than hydrogen; R₂X is a halogen;or X is O, S, NR₇, CO, OCO, or OCS; when X is O or S, R₂ is hydrogen,alkyl, aryl, R₈CO—, R₈OCO—, R₈SCO, R₈OCS— or a moiety that is removableunder physiological conditions, where R₈ is alkyl or aryl; when X isNR₇, R₂ and R₇ are independently hydrogen, alkyl, aryl, R₈CO—, R₈OCO—,or a moiety that is removable under physiological conditions; when X isCO, OCO or OCS, R₂ is hydrogen, alkyl, aryl, or a moiety that isremovable under physiological conditions; n is 1 or 2; R₃ is halogen,alkyl, haloalkyl, alkenyl, alkenol, alkanol, or haloalkenyl; R₄ and R₅are N; or R₄ is N and R₅ is CH; R₆ is hydrogen or alkyl; and A is oxygenor sulfur; or a salt thereof.
 2. The pharmaceutical composition of claim1 wherein A is oxygen, R₂ is hydrogen, R₃ is allyl, and R₄ and R₅ are N.3. The pharmaceutical composition of claim 2 wherein n is
 1. 4. Apharmaceutical composition comprising a means for enhancing theactivation of procaspase-3 in a cancer cell, and a pharmaceuticallyacceptable carrier, wherein the means for enhancing the activation ofprocaspase-3 in a cancer cell is a compound of Formula ZZ:

wherein two of R_(a), R_(b), R_(e), R_(d) and R_(e) are (C₁-C₃)alkyl,(C₁-C₃)alkoxy or halogen and the remaining groups are hydrogen; each Ris independently hydrogen, halogen, alkoxy, alkenyl, or alkyl; R₂X is ahalogen; or X is O, S, NR₇, CO, OCO, or OCS; when X is 0 or 5, R₂ ishydrogen, alkyl, aryl, R₈CO—, R₈OCO—, R₈SCO, R₈OCS— or a moiety that isremovable under physiological conditions, where R₈ is alkyl or aryl;when X is NR₇, R₂ and R₇ are independently hydrogen, alkyl, aryl, R₈CO—,R₈OCO—, or a moiety that is removable under physiological conditions;when X is CO, OCO or OCS, R₂ is hydrogen, alkyl, aryl, or a moiety thatis removable under physiological conditions; n is 1 or 2; R₃ is halogen,alkyl, haloalkyl, alkenyl, alkenol, alkanol, or haloalkenyl; R₄ and R₅are N; or R₄ is N and R₅ is CH; R₆ is hydrogen or alkyl; and A is oxygenor sulfur; or a salt thereof.
 5. The pharmaceutical composition of claim4 wherein A is oxygen, R₂ is hydrogen, R₃ is allyl, R₄ and R₅ are N, andn is
 1. 6. A pharmaceutical composition comprising a means for enhancingthe activation of procaspase-3 in a cancer cell, and a pharmaceuticallyacceptable carrier, wherein the means is a procaspase-3 activatingcompound wherein the compound is: